https://trial.medpath.com/news/ractigen-garners-orphan-drug-designation-for-sarna-therapy-rag-18-cgtlive-r 2024-09-05T18:14:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ractigen-garners-orphan-drug-designation-for-sarna-therapy-rag-18-cgtlive-r 2024-09-05T18:14:17+00:00 weekly 0.7 https://trial.medpath.com/news/bird-influenza-study-clinical-trial-rochester-clinical-research 2024-09-05T17:28:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bird-influenza-study-clinical-trial-rochester-clinical-research 2024-09-05T17:28:55+00:00 weekly 0.7 https://trial.medpath.com/news/arsenal-biosciences-raises-325m-in-series-c-financing-round 2024-09-05T17:12:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arsenal-biosciences-raises-325m-in-series-c-financing-round 2024-09-05T17:12:05+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-says-experimental-insulin-could-mean-313-fewer-injections-per-year-quartz 2024-09-05T17:10:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-says-experimental-insulin-could-mean-313-fewer-injections-per-year-quartz 2024-09-05T17:10:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-medigene-s-ind-for-tcr-t-therapy-in-certain-advanced-solid-tumors 2024-09-05T16:51:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-medigene-s-ind-for-tcr-t-therapy-in-certain-advanced-solid-tumors 2024-09-05T16:51:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designation-to-vmt01-for-unresectable-metastatic-mc1r-melanoma 2024-09-05T16:26:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designation-to-vmt01-for-unresectable-metastatic-mc1r-melanoma 2024-09-05T16:26:30+00:00 weekly 0.7 https://trial.medpath.com/news/balloon-angioplasty-vs-medical-management-for-intracranial-artery-stenosis-jama-network 2024-09-05T15:56:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/balloon-angioplasty-vs-medical-management-for-intracranial-artery-stenosis-jama-network 2024-09-05T15:56:19+00:00 weekly 0.7 https://trial.medpath.com/news/study-aims-to-find-new-ways-of-alleviating-the-long-term-effects-of-covid-19-news-medical 2024-09-05T15:47:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-aims-to-find-new-ways-of-alleviating-the-long-term-effects-of-covid-19-news-medical 2024-09-05T15:47:37+00:00 weekly 0.7 https://trial.medpath.com/news/race-ethnicity-and-sex-in-pediatric-eye-disease-investigator-group-clinical-studies 2024-09-05T15:05:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/race-ethnicity-and-sex-in-pediatric-eye-disease-investigator-group-clinical-studies 2024-09-05T15:05:36+00:00 weekly 0.7 https://trial.medpath.com/news/hoth-therapeutics-announces-expansion-of-clinical-sites-for-ht-001-phase-2a-trial 2024-09-05T14:47:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hoth-therapeutics-announces-expansion-of-clinical-sites-for-ht-001-phase-2a-trial 2024-09-05T14:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/french-biotech-candidate-for-cannabis-use-disorder-fails-phase-2b-clinical-trial-indivior 2024-09-05T14:35:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/french-biotech-candidate-for-cannabis-use-disorder-fails-phase-2b-clinical-trial-indivior 2024-09-05T14:35:14+00:00 weekly 0.7 https://trial.medpath.com/news/dmid-nextgen-covid-19-vaccines-fill-finish-a-platform-trial-to-evaluate-next 2024-09-05T14:34:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dmid-nextgen-covid-19-vaccines-fill-finish-a-platform-trial-to-evaluate-next 2024-09-05T14:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-chmp-gives-green-light-to-new-covid-vaccine-marketscreener 2024-09-05T14:26:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-chmp-gives-green-light-to-new-covid-vaccine-marketscreener 2024-09-05T14:26:03+00:00 weekly 0.7 https://trial.medpath.com/news/prokidney-drops-phase-iii-ckd-study-to-focus-on-us-market-and-save-up-to-175m 2024-09-05T14:25:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prokidney-drops-phase-iii-ckd-study-to-focus-on-us-market-and-save-up-to-175m 2024-09-05T14:25:10+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-cbd-dosing-reduces-daytime-fatigue-compared-to-placebo-norml 2024-09-05T14:07:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-cbd-dosing-reduces-daytime-fatigue-compared-to-placebo-norml 2024-09-05T14:07:18+00:00 weekly 0.7 https://trial.medpath.com/news/pantheon-vision-pioneers-bioengineered-solutions-to-combat-global-corneal-blindness 2024-09-05T14:00:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pantheon-vision-pioneers-bioengineered-solutions-to-combat-global-corneal-blindness 2024-09-05T14:00:30+00:00 weekly 0.7 https://trial.medpath.com/news/tofu-like-psychedelic-gets-fda-nod-mindstate-s-ai-designed-therapy-to-begin-human-trials 2024-09-05T13:16:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tofu-like-psychedelic-gets-fda-nod-mindstate-s-ai-designed-therapy-to-begin-human-trials 2024-09-05T13:16:10+00:00 weekly 0.7 https://trial.medpath.com/news/webinar-provides-details-on-compass-pws-clinical-trial 2024-09-05T12:39:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/webinar-provides-details-on-compass-pws-clinical-trial 2024-09-05T12:39:54+00:00 weekly 0.7 https://trial.medpath.com/news/sophia-genetics-announces-validation-of-novel-clinical-trial-assay-together-pr-newswire 2024-09-05T12:30:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sophia-genetics-announces-validation-of-novel-clinical-trial-assay-together-pr-newswire 2024-09-05T12:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-btk-inhibitor-shines-in-multiple-sclerosis-trial-clinical-trials-arena 2024-09-05T12:03:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-btk-inhibitor-shines-in-multiple-sclerosis-trial-clinical-trials-arena 2024-09-05T12:03:43+00:00 weekly 0.7 https://trial.medpath.com/news/ai-driven-insights-soms-boosts-clinical-trial-success-outsourcing-pharma-com 2024-09-05T11:09:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-driven-insights-soms-boosts-clinical-trial-success-outsourcing-pharma-com 2024-09-05T11:09:31+00:00 weekly 0.7 https://trial.medpath.com/news/unitedhealthcare-launches-nationwide-gold-card-program-to-streamline-prior-authorization-process 2024-09-05T08:59:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unitedhealthcare-launches-nationwide-gold-card-program-to-streamline-prior-authorization-process 2024-09-05T08:59:58+00:00 weekly 0.7 https://trial.medpath.com/news/first-time-disclosures-from-rome 2024-09-05T08:49:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-time-disclosures-from-rome 2024-09-05T08:49:06+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-enrolled-in-a-clinical-trial-to-evaluate-brain-next-generation-cognitive-training 2024-09-05T07:50:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-enrolled-in-a-clinical-trial-to-evaluate-brain-next-generation-cognitive-training 2024-09-05T07:50:10+00:00 weekly 0.7 https://trial.medpath.com/news/crestone-announces-positive-data-from-phase-2-clinical-trial-of-crs3123-for-c-difficile 2024-09-05T07:44:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crestone-announces-positive-data-from-phase-2-clinical-trial-of-crs3123-for-c-difficile 2024-09-05T07:44:32+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-for-groundbreaking-alzheimer-s-disease-drug-begins-in-middle-tennessee 2024-09-05T02:50:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-for-groundbreaking-alzheimer-s-disease-drug-begins-in-middle-tennessee 2024-09-05T02:50:32+00:00 weekly 0.7 https://trial.medpath.com/news/uk-takes-bold-step-to-ban-xylazine-and-21-other-substances-in-major-drug-control-initiative 2024-09-05T02:22:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-takes-bold-step-to-ban-xylazine-and-21-other-substances-in-major-drug-control-initiative 2024-09-05T02:22:02+00:00 weekly 0.7 https://trial.medpath.com/news/hoth-therapeutics-announces-positive-data-from-first-of-its-kind-human 2024-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hoth-therapeutics-announces-positive-data-from-first-of-its-kind-human 2024-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/blinatumomab-improves-survival-in-pediatric-high-risk-b-all-post-transplant 2024-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blinatumomab-improves-survival-in-pediatric-high-risk-b-all-post-transplant 2024-09-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/evommune-enrols-first-subject-in-chronic-inducible-urticaria-therapy-trial 2024-09-04T23:49:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evommune-enrols-first-subject-in-chronic-inducible-urticaria-therapy-trial 2024-09-04T23:49:27+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-to-investigate-causes-of-diabetes-obesity-in-individuals-with-spinal-cord-injury 2024-09-04T22:19:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-to-investigate-causes-of-diabetes-obesity-in-individuals-with-spinal-cord-injury 2024-09-04T22:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/emapalumab-extends-intervention-free-survival-for-children-with-hlh 2024-09-04T22:07:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emapalumab-extends-intervention-free-survival-for-children-with-hlh 2024-09-04T22:07:14+00:00 weekly 0.7 https://trial.medpath.com/news/adding-anti-clotting-drugs-to-stroke-care-ineffective-clinical-trial-finds 2024-09-04T21:07:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adding-anti-clotting-drugs-to-stroke-care-ineffective-clinical-trial-finds 2024-09-04T21:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/axsome-therapeutics-announces-fda-acceptance-of-nda-resubmission-for-axs-07-for-the-acute-treatment-of-migraine 2024-09-04T20:09:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/axsome-therapeutics-announces-fda-acceptance-of-nda-resubmission-for-axs-07-for-the-acute-treatment-of-migraine 2024-09-04T20:09:25+00:00 weekly 0.7 https://trial.medpath.com/news/btcrc-lun17-127-published-in-lung-cancer-journal 2024-09-04T19:29:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/btcrc-lun17-127-published-in-lung-cancer-journal 2024-09-04T19:29:43+00:00 weekly 0.7 https://trial.medpath.com/news/regenxbio-s-mpsii-gene-therapy-rgx-121-continues-to-show-efficacy-in-long-term-trial-data 2024-09-04T18:59:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regenxbio-s-mpsii-gene-therapy-rgx-121-continues-to-show-efficacy-in-long-term-trial-data 2024-09-04T18:59:57+00:00 weekly 0.7 https://trial.medpath.com/news/marshall-university-launches-latest-clinical-trial-cohort-for-non-opioid-treatment-of-neonatal 2024-09-04T18:27:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marshall-university-launches-latest-clinical-trial-cohort-for-non-opioid-treatment-of-neonatal 2024-09-04T18:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-ib-ii-randomized-clinical-trial-of-oleclumab-with-or-without-durvalumab-aacr-journals 2024-09-04T18:10:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-ib-ii-randomized-clinical-trial-of-oleclumab-with-or-without-durvalumab-aacr-journals 2024-09-04T18:10:35+00:00 weekly 0.7 https://trial.medpath.com/news/enhancing-patient-selection-in-sepsis-clinical-trials-design-through-an-ai-enrichment-strategy 2024-09-04T17:28:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enhancing-patient-selection-in-sepsis-clinical-trials-design-through-an-ai-enrichment-strategy 2024-09-04T17:28:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-activity-recap-august-2024-features-tcr-t-cell-therapy-approval-rems 2024-09-04T17:18:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-activity-recap-august-2024-features-tcr-t-cell-therapy-approval-rems 2024-09-04T17:18:02+00:00 weekly 0.7 https://trial.medpath.com/news/bill-gates-optimistic-of-progress-in-tb-vaccine-clinical-trial-news-agency-of-nigeria 2024-09-04T15:59:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bill-gates-optimistic-of-progress-in-tb-vaccine-clinical-trial-news-agency-of-nigeria 2024-09-04T15:59:06+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-a-study-to-assess-the-safety-and-efficacy-of-lacosamide-versus-placebo-a 2024-09-04T15:55:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-a-study-to-assess-the-safety-and-efficacy-of-lacosamide-versus-placebo-a 2024-09-04T15:55:10+00:00 weekly 0.7 https://trial.medpath.com/news/heart-drug-improves-exercise-tolerance-in-clinical-trial-of-patients-with-hypertrophic 2024-09-04T15:29:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heart-drug-improves-exercise-tolerance-in-clinical-trial-of-patients-with-hypertrophic 2024-09-04T15:29:47+00:00 weekly 0.7 https://trial.medpath.com/news/outlook-therapeutics-r-announces-completion-of-enrollment-in-norse-eight-clinical-trial 2024-09-04T14:58:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/outlook-therapeutics-r-announces-completion-of-enrollment-in-norse-eight-clinical-trial 2024-09-04T14:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/radiation-oncology-research-and-clinical-trial-res-newswise 2024-09-04T14:20:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/radiation-oncology-research-and-clinical-trial-res-newswise 2024-09-04T14:20:50+00:00 weekly 0.7 https://trial.medpath.com/news/i-wanted-to-change-the-outcomes-sholler-s-career-leads-to-neuroblastoma-breakthrough 2024-09-04T13:46:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-wanted-to-change-the-outcomes-sholler-s-career-leads-to-neuroblastoma-breakthrough 2024-09-04T13:46:29+00:00 weekly 0.7 https://trial.medpath.com/news/abbott-initiates-clinical-study-to-evaluate-the-use-of-its-deep-brain-stimulation-system-to 2024-09-04T13:07:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbott-initiates-clinical-study-to-evaluate-the-use-of-its-deep-brain-stimulation-system-to 2024-09-04T13:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/nh-theraguix-advances-phase-ii-brain-metastases-treatment-trial 2024-09-04T11:48:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nh-theraguix-advances-phase-ii-brain-metastases-treatment-trial 2024-09-04T11:48:02+00:00 weekly 0.7 https://trial.medpath.com/news/eledon-announces-completion-of-enrollment-in-phase-2-bestow-clinical-trial-assessing 2024-09-04T11:29:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eledon-announces-completion-of-enrollment-in-phase-2-bestow-clinical-trial-assessing 2024-09-04T11:29:16+00:00 weekly 0.7 https://trial.medpath.com/news/avenzo-gilead-partner-for-breast-cancer-combination-regimen-trial 2024-09-04T11:22:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/avenzo-gilead-partner-for-breast-cancer-combination-regimen-trial 2024-09-04T11:22:47+00:00 weekly 0.7 https://trial.medpath.com/news/invivyd-doses-first-participants-in-phase-1-clinical-trial-of-vyd2311-a-next-generation 2024-09-04T11:08:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invivyd-doses-first-participants-in-phase-1-clinical-trial-of-vyd2311-a-next-generation 2024-09-04T11:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-bluerock-s-ind-for-photoreceptor-diseases-therapy-trial 2024-09-04T11:08:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-bluerock-s-ind-for-photoreceptor-diseases-therapy-trial 2024-09-04T11:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-eyebio-announce-initiation-of-phase-2b-3-clinical-trial-for-restorettm-for-the 2024-09-04T10:54:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-and-eyebio-announce-initiation-of-phase-2b-3-clinical-trial-for-restorettm-for-the 2024-09-04T10:54:27+00:00 weekly 0.7 https://trial.medpath.com/news/immunic-announces-first-patient-enrolled-in-investigator-sponsored-phase-2-clinical-trial 2024-09-04T10:30:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunic-announces-first-patient-enrolled-in-investigator-sponsored-phase-2-clinical-trial 2024-09-04T10:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/wearable-heart-monitor-ups-detection-of-a-fib-by-more-than-50 2024-09-04T10:09:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wearable-heart-monitor-ups-detection-of-a-fib-by-more-than-50 2024-09-04T10:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/september-4-2024-nih-heal-initiative-supports-new-funding-opportunity-for-pragmatic 2024-09-04T08:01:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/september-4-2024-nih-heal-initiative-supports-new-funding-opportunity-for-pragmatic 2024-09-04T08:01:46+00:00 weekly 0.7 https://trial.medpath.com/news/exciting-developments-in-clinical-research-axcellant-s-groundbreaking-global-study 2024-09-04T07:20:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exciting-developments-in-clinical-research-axcellant-s-groundbreaking-global-study 2024-09-04T07:20:15+00:00 weekly 0.7 https://trial.medpath.com/news/phase-i-ib-clinical-trial-of-sabatolimab-an-anti-tim-3-antibody-alone-and-in-combination 2024-09-04T04:35:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-i-ib-clinical-trial-of-sabatolimab-an-anti-tim-3-antibody-alone-and-in-combination 2024-09-04T04:35:45+00:00 weekly 0.7 https://trial.medpath.com/news/end-of-trial-declaration-clinical-trials-toolkit 2024-09-04T01:55:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/end-of-trial-declaration-clinical-trials-toolkit 2024-09-04T01:55:17+00:00 weekly 0.7 https://trial.medpath.com/news/irlab-strengthens-patent-portfolio-for-parkinson-s-drug-candidates-mesdopetam-and-pirepemat 2024-09-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irlab-strengthens-patent-portfolio-for-parkinson-s-drug-candidates-mesdopetam-and-pirepemat 2024-09-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/denali-therapeutics-plans-accelerated-approval-for-mps-ii-treatment 2024-09-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/denali-therapeutics-plans-accelerated-approval-for-mps-ii-treatment 2024-09-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-hope-for-progressive-supranuclear-palsy-with-innovative-trial-uc-san-francisco 2024-09-03T23:40:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-hope-for-progressive-supranuclear-palsy-with-innovative-trial-uc-san-francisco 2024-09-03T23:40:14+00:00 weekly 0.7 https://trial.medpath.com/news/giving-resources-to-low-income-children-to-enhance-recovery-clinical-trial-identifier 2024-09-03T21:54:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/giving-resources-to-low-income-children-to-enhance-recovery-clinical-trial-identifier 2024-09-03T21:54:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-ind-for-phase-2-clinical-trial-evaluating-treatment-for-post-covid-19-condition 2024-09-03T21:49:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-authorizes-ind-for-phase-2-clinical-trial-evaluating-treatment-for-post-covid-19-condition 2024-09-03T21:49:22+00:00 weekly 0.7 https://trial.medpath.com/news/ascendis-pharma-reports-second-quarter-2024-financial-results-and-updates-on-clinical-trials 2024-09-03T21:04:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascendis-pharma-reports-second-quarter-2024-financial-results-and-updates-on-clinical-trials 2024-09-03T21:04:00+00:00 weekly 0.7 https://trial.medpath.com/news/theolytics-secures-grant-from-innovate-uk-for-phase-i-trial-of-ovarian-cancer-drug 2024-09-03T20:47:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/theolytics-secures-grant-from-innovate-uk-for-phase-i-trial-of-ovarian-cancer-drug 2024-09-03T20:47:09+00:00 weekly 0.7 https://trial.medpath.com/news/grit-biotechnology-s-til-therapy-gt201-cleared-for-us-trial-in-advanced-solid-tumors 2024-09-03T20:35:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grit-biotechnology-s-til-therapy-gt201-cleared-for-us-trial-in-advanced-solid-tumors 2024-09-03T20:35:04+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-announces-fda-acceptance-of-new-drug-application-for-sebetralstat-for-oral-on-demand-treatment-of-hereditary-angioedema 2024-09-03T20:09:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kalvista-announces-fda-acceptance-of-new-drug-application-for-sebetralstat-for-oral-on-demand-treatment-of-hereditary-angioedema 2024-09-03T20:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/athira-pharma-announces-topline-results-from-phase-2-3-lift-ad-clinical-trial-of 2024-09-03T20:06:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/athira-pharma-announces-topline-results-from-phase-2-3-lift-ad-clinical-trial-of 2024-09-03T20:06:46+00:00 weekly 0.7 https://trial.medpath.com/news/kezar-study-evaluates-potential-new-treatment-for-people-with-lupus-nephritis 2024-09-03T19:14:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kezar-study-evaluates-potential-new-treatment-for-people-with-lupus-nephritis 2024-09-03T19:14:15+00:00 weekly 0.7 https://trial.medpath.com/news/structural-news-clinical-trials-scai 2024-09-03T18:58:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/structural-news-clinical-trials-scai 2024-09-03T18:58:40+00:00 weekly 0.7 https://trial.medpath.com/news/new-experimental-drug-aims-to-extend-dogs-lives-pill-available-locally-in-clinical-trial 2024-09-03T18:25:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-experimental-drug-aims-to-extend-dogs-lives-pill-available-locally-in-clinical-trial 2024-09-03T18:25:13+00:00 weekly 0.7 https://trial.medpath.com/news/7-hills-pharma-safely-doses-first-patient-in-phase-1b-2a-clinical-trial-testing-alintegimod 2024-09-03T18:08:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/7-hills-pharma-safely-doses-first-patient-in-phase-1b-2a-clinical-trial-testing-alintegimod 2024-09-03T18:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/vaxcyte-shares-boom-as-one-of-biotech-s-big-david-vs-goliath-stories-heats-up 2024-09-03T17:35:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaxcyte-shares-boom-as-one-of-biotech-s-big-david-vs-goliath-stories-heats-up 2024-09-03T17:35:39+00:00 weekly 0.7 https://trial.medpath.com/news/exclusive-to-roswell-park-armored-car-clinical-trial-targets-cd19-hematologic-malignancies 2024-09-03T17:33:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exclusive-to-roswell-park-armored-car-clinical-trial-targets-cd19-hematologic-malignancies 2024-09-03T17:33:54+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-august-tigris-trial-update-biospace 2024-09-03T17:24:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-provides-august-tigris-trial-update-biospace 2024-09-03T17:24:31+00:00 weekly 0.7 https://trial.medpath.com/news/dyne-therapeutics-announces-positive-new-clinical-data-from-phase-1-2-deliver-trial-of 2024-09-03T17:16:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dyne-therapeutics-announces-positive-new-clinical-data-from-phase-1-2-deliver-trial-of 2024-09-03T17:16:52+00:00 weekly 0.7 https://trial.medpath.com/news/jcr-pharmaceuticals-announces-completion-of-clinical-trial-notification-process-in-japan 2024-09-03T16:46:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jcr-pharmaceuticals-announces-completion-of-clinical-trial-notification-process-in-japan 2024-09-03T16:46:20+00:00 weekly 0.7 https://trial.medpath.com/news/apolipoprotein-a-i-infusions-and-cardiovascular-outcomes-in-acute-myocardial-infarction 2024-09-03T16:13:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apolipoprotein-a-i-infusions-and-cardiovascular-outcomes-in-acute-myocardial-infarction 2024-09-03T16:13:09+00:00 weekly 0.7 https://trial.medpath.com/news/gc-biopharma-and-hanmi-pharmaceutical-receives-ind-clearance-for-phase-1-2-clinical 2024-09-03T15:58:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gc-biopharma-and-hanmi-pharmaceutical-receives-ind-clearance-for-phase-1-2-clinical 2024-09-03T15:58:35+00:00 weekly 0.7 https://trial.medpath.com/news/recursion-presents-mixed-data-on-lead-ai-derived-drug-candidate-for-potentially-fatal-brain-condition 2024-09-03T15:30:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recursion-presents-mixed-data-on-lead-ai-derived-drug-candidate-for-potentially-fatal-brain-condition 2024-09-03T15:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-wegovy-won-t-raise-user-s-suicide-risk-study-finds 2024-09-03T15:09:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-wegovy-won-t-raise-user-s-suicide-risk-study-finds 2024-09-03T15:09:31+00:00 weekly 0.7 https://trial.medpath.com/news/antabio-completes-phase-1-clinical-study-of-mem-ant3310-for-severe-hospital-infections 2024-09-03T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/antabio-completes-phase-1-clinical-study-of-mem-ant3310-for-severe-hospital-infections 2024-09-03T15:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/vaxcyte-reports-positive-topline-data-from-phase-1-2-study-of-vax-31-its-31-valent 2024-09-03T14:37:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaxcyte-reports-positive-topline-data-from-phase-1-2-study-of-vax-31-its-31-valent 2024-09-03T14:37:23+00:00 weekly 0.7 https://trial.medpath.com/news/adaptimmune-s-journey-to-pioneering-tcr-t-therapy-for-cancer-treatment 2024-09-03T13:12:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adaptimmune-s-journey-to-pioneering-tcr-t-therapy-for-cancer-treatment 2024-09-03T13:12:33+00:00 weekly 0.7 https://trial.medpath.com/news/biomx-to-present-positive-phase-1b-2a-clinical-trial-data-for-bx004-at-the-european 2024-09-03T12:41:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biomx-to-present-positive-phase-1b-2a-clinical-trial-data-for-bx004-at-the-european 2024-09-03T12:41:26+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-accelerator-partners-with-tau-medical-for-early-feasibility-study-of-pivot-extend-in 2024-09-03T10:52:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-accelerator-partners-with-tau-medical-for-early-feasibility-study-of-pivot-extend-in 2024-09-03T10:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-advances-ambition-to-improve-standards-of-care-in-multiple-cancer-types-at 2024-09-03T06:05:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-advances-ambition-to-improve-standards-of-care-in-multiple-cancer-types-at 2024-09-03T06:05:39+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-aims-to-redefine-the-future-of-respiratory-medicine-at-the-european-respiratory-society 2024-09-03T06:03:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-aims-to-redefine-the-future-of-respiratory-medicine-at-the-european-respiratory-society 2024-09-03T06:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/valneva-and-pfizer-report-further-positive-phase-2-booster-results-for-lyme-disease 2024-09-03T05:02:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valneva-and-pfizer-report-further-positive-phase-2-booster-results-for-lyme-disease 2024-09-03T05:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/quality-of-life-measures-to-become-commonplace-in-cancer-clinical-trials 2024-09-03T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quality-of-life-measures-to-become-commonplace-in-cancer-clinical-trials 2024-09-03T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/news/quanthealth-215-million-in-financial-returns-and-85-clinical-trial-accuracy 2024-09-03T02:39:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quanthealth-215-million-in-financial-returns-and-85-clinical-trial-accuracy 2024-09-03T02:39:25+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-efficacy-of-cholecalciferol-and-silymarin-in-improving-lower-urinary-tract 2024-09-03T02:28:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaluation-of-efficacy-of-cholecalciferol-and-silymarin-in-improving-lower-urinary-tract 2024-09-03T02:28:55+00:00 weekly 0.7 https://trial.medpath.com/news/emyria-announces-interim-clinical-trial-results-for-ptsd-program-biotech-dispatch 2024-09-03T01:40:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emyria-announces-interim-clinical-trial-results-for-ptsd-program-biotech-dispatch 2024-09-03T01:40:21+00:00 weekly 0.7 https://trial.medpath.com/news/signed-agreement-for-the-clinical-trial-of-bnct-with-national-cancer-center-stella 2024-09-03T01:11:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/signed-agreement-for-the-clinical-trial-of-bnct-with-national-cancer-center-stella 2024-09-03T01:11:48+00:00 weekly 0.7 https://trial.medpath.com/news/unicycive-therapeutics-announces-submission-of-the-new-drug-application-nda-to-the-u-s-fda-for-oxylanthanum-carbonate-olc-for-the-treatment-of-hyperphosphatemia-in-patients-with-chronic-kidney-disease-on-dialysis 2024-09-03T01:09:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unicycive-therapeutics-announces-submission-of-the-new-drug-application-nda-to-the-u-s-fda-for-oxylanthanum-carbonate-olc-for-the-treatment-of-hyperphosphatemia-in-patients-with-chronic-kidney-disease-on-dialysis 2024-09-03T01:09:22+00:00 weekly 0.7 https://trial.medpath.com/news/longeveron-r-announces-positive-type-c-meeting-with-u-s-fda-regarding-pathway-to-bla-for-lomecel-btm-in-hypoplastic-left-heart-syndrome-hlhs 2024-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longeveron-r-announces-positive-type-c-meeting-with-u-s-fda-regarding-pathway-to-bla-for-lomecel-btm-in-hypoplastic-left-heart-syndrome-hlhs 2024-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-fast-track-designations-to-caribou-biosciences-cb-010-and-cb-012-for-refractory-sle-and-aml 2024-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-fast-track-designations-to-caribou-biosciences-cb-010-and-cb-012-for-refractory-sle-and-aml 2024-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/urticaria-emerges-as-concern-in-phase-1-trial-of-hiv-mrna-vaccines 2024-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urticaria-emerges-as-concern-in-phase-1-trial-of-hiv-mrna-vaccines 2024-09-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/challenges-and-opportunities-in-developing-an-oncology-clinical-trial-network-in-the-urotoday 2024-09-02T22:08:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/challenges-and-opportunities-in-developing-an-oncology-clinical-trial-network-in-the-urotoday 2024-09-02T22:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/gnrh-a-based-fertility-sparing-treatment-of-atypical-endometrial-hyperplasia-aeh-and 2024-09-02T21:57:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gnrh-a-based-fertility-sparing-treatment-of-atypical-endometrial-hyperplasia-aeh-and 2024-09-02T21:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/first-dengue-vaccine-phase-3-clinical-trial-kicks-off-at-kims-odisha-diary 2024-09-02T19:42:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-dengue-vaccine-phase-3-clinical-trial-kicks-off-at-kims-odisha-diary 2024-09-02T19:42:00+00:00 weekly 0.7 https://trial.medpath.com/news/nxera-wins-35m-after-phase-ii-schizophrenia-trial-success-clinical-trials-arena 2024-09-02T16:45:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nxera-wins-35m-after-phase-ii-schizophrenia-trial-success-clinical-trials-arena 2024-09-02T16:45:14+00:00 weekly 0.7 https://trial.medpath.com/news/re-engineering-the-clinical-approach-to-suspected-cardiac-chest-pain-assessment-in-the 2024-09-02T16:11:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/re-engineering-the-clinical-approach-to-suspected-cardiac-chest-pain-assessment-in-the 2024-09-02T16:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-moves-investigator-led-oncology-cell-therapy-trial-terminated 2024-09-02T15:42:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pipeline-moves-investigator-led-oncology-cell-therapy-trial-terminated 2024-09-02T15:42:47+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-has-positive-long-term-extravascular-icd-study-results-massdevice 2024-09-02T15:39:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-has-positive-long-term-extravascular-icd-study-results-massdevice 2024-09-02T15:39:01+00:00 weekly 0.7 https://trial.medpath.com/news/multiple-sclerosis-pill-succeeds-in-key-trial-sanofi-says-stat-news 2024-09-02T15:02:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/multiple-sclerosis-pill-succeeds-in-key-trial-sanofi-says-stat-news 2024-09-02T15:02:21+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-experience-with-a-new-solvent-detergent-treated-intravenous-immunoglobulin-free-of 2024-09-02T14:20:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-experience-with-a-new-solvent-detergent-treated-intravenous-immunoglobulin-free-of 2024-09-02T14:20:20+00:00 weekly 0.7 https://trial.medpath.com/news/proteus-trial-suggests-ai-for-heart-scans-may-benefit-decision-making-for-less 2024-09-02T14:18:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/proteus-trial-suggests-ai-for-heart-scans-may-benefit-decision-making-for-less 2024-09-02T14:18:03+00:00 weekly 0.7 https://trial.medpath.com/news/minimal-residual-disease-status-may-be-linked-with-progression-free-survival-in-cll 2024-09-02T14:06:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minimal-residual-disease-status-may-be-linked-with-progression-free-survival-in-cll 2024-09-02T14:06:24+00:00 weekly 0.7 https://trial.medpath.com/news/association-between-in-vitro-susceptibility-and-clinical-outcomes-in-fungal-keratitis 2024-09-02T13:37:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/association-between-in-vitro-susceptibility-and-clinical-outcomes-in-fungal-keratitis 2024-09-02T13:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/drug-coated-balloon-angioplasty-with-rescue-stenting-versus-intended-stenting-for-the 2024-09-02T13:29:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-coated-balloon-angioplasty-with-rescue-stenting-versus-intended-stenting-for-the 2024-09-02T13:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/optical-coherence-tomography-guided-coronary-intervention-in-patients-with-complex-lesions 2024-09-02T13:29:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optical-coherence-tomography-guided-coronary-intervention-in-patients-with-complex-lesions 2024-09-02T13:29:06+00:00 weekly 0.7 https://trial.medpath.com/news/esc-congress-2024-infinity-swedeheart-trial-of-elixir-medical-s-dynamx-bioadaptor 2024-09-02T13:20:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esc-congress-2024-infinity-swedeheart-trial-of-elixir-medical-s-dynamx-bioadaptor 2024-09-02T13:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-teeing-up-drug-trials-los-angeles-business-journal 2024-09-02T13:02:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arrowhead-teeing-up-drug-trials-los-angeles-business-journal 2024-09-02T13:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/artificial-intelligence-guided-screening-for-cardiomyopathies-in-an-obstetric-population 2024-09-02T12:28:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/artificial-intelligence-guided-screening-for-cardiomyopathies-in-an-obstetric-population 2024-09-02T12:28:52+00:00 weekly 0.7 https://trial.medpath.com/news/dr-noah-biotech-s-ai-driven-als-medicine-receives-u-s-fda-approval-for-phase-1 2024-09-02T11:23:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-noah-biotech-s-ai-driven-als-medicine-receives-u-s-fda-approval-for-phase-1 2024-09-02T11:23:02+00:00 weekly 0.7 https://trial.medpath.com/news/pulmonary-vein-isolation-vs-sham-intervention-in-symptomatic-atrial-fibrillation 2024-09-02T10:55:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pulmonary-vein-isolation-vs-sham-intervention-in-symptomatic-atrial-fibrillation 2024-09-02T10:55:47+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-fda-approval-for-nipocalimab-in-generalized-myasthenia-gravis 2024-09-02T10:25:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-seeks-fda-approval-for-nipocalimab-in-generalized-myasthenia-gravis 2024-09-02T10:25:01+00:00 weekly 0.7 https://trial.medpath.com/news/io-biotech-updates-on-pivotal-phase-3-trial-of-io102-io103-in-combination-with-biospace 2024-09-02T10:04:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/io-biotech-updates-on-pivotal-phase-3-trial-of-io102-io103-in-combination-with-biospace 2024-09-02T10:04:05+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-efficacy-of-probing-with-or-without-intubation-and-or-inferior-turbinate-fracture-in 2024-09-02T09:49:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparative-efficacy-of-probing-with-or-without-intubation-and-or-inferior-turbinate-fracture-in 2024-09-02T09:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/we-will-be-forever-grateful-mother-s-joy-as-son-s-leukaemia-stays-in-remission-for-five-years 2024-09-02T09:47:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/we-will-be-forever-grateful-mother-s-joy-as-son-s-leukaemia-stays-in-remission-for-five-years 2024-09-02T09:47:55+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-s-camzyos-offers-benefits-in-ohcm-trial 2024-09-02T08:46:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-s-camzyos-offers-benefits-in-ohcm-trial 2024-09-02T08:46:19+00:00 weekly 0.7 https://trial.medpath.com/news/global-progress-in-clinical-research-on-human-respiratory-syncytial-virus-vaccines-frontiers 2024-09-02T08:19:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-progress-in-clinical-research-on-human-respiratory-syncytial-virus-vaccines-frontiers 2024-09-02T08:19:01+00:00 weekly 0.7 https://trial.medpath.com/news/effects-of-meridian-sinew-tuina-after-identifying-the-treatment-area-under-ultrasound-frontiers 2024-09-02T08:19:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effects-of-meridian-sinew-tuina-after-identifying-the-treatment-area-under-ultrasound-frontiers 2024-09-02T08:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-tolebrutinib-meets-primary-endpoint-in-hercules-phase-3-study-the-first-sanofi 2024-09-02T05:08:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-tolebrutinib-meets-primary-endpoint-in-hercules-phase-3-study-the-first-sanofi 2024-09-02T05:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-pharmaceuticals-presents-new-pivotal-phase-3-data-at-esc-2024-from-palisade-study-of-plozasiran-in-patients-with-familial-chylomicronemia-syndrome 2024-09-02T04:09:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arrowhead-pharmaceuticals-presents-new-pivotal-phase-3-data-at-esc-2024-from-palisade-study-of-plozasiran-in-patients-with-familial-chylomicronemia-syndrome 2024-09-02T04:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-annouces-multiple-clinical-study-results-of-mazdutide-to-be-presented-at-the-easd-2024 2024-09-02T00:19:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovent-annouces-multiple-clinical-study-results-of-mazdutide-to-be-presented-at-the-easd-2024 2024-09-02T00:19:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-ii-clinical-trial-of-toripalimab-in-advanced-solid-tumors-with-polymerase-epsilon 2024-09-02T00:03:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-phase-ii-clinical-trial-of-toripalimab-in-advanced-solid-tumors-with-polymerase-epsilon 2024-09-02T00:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/incorporating-a-stepped-care-approach-into-internet-based 2024-09-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/incorporating-a-stepped-care-approach-into-internet-based 2024-09-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/roche-s-piasky-approved-in-eu-as-first-monthly-self-administered-treatment-for-paroxysmal-nocturnal-haemoglobinuria 2024-09-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-s-piasky-approved-in-eu-as-first-monthly-self-administered-treatment-for-paroxysmal-nocturnal-haemoglobinuria 2024-09-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/esc-2024-cathedral-hf-trial-results-have-the-potential-to-reduce-polypharmacy 2024-09-01T23:46:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esc-2024-cathedral-hf-trial-results-have-the-potential-to-reduce-polypharmacy 2024-09-01T23:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/closing-the-loop-with-transcranial-electrical-stimulation-for-depression-psychiatry-online 2024-09-01T22:51:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/closing-the-loop-with-transcranial-electrical-stimulation-for-depression-psychiatry-online 2024-09-01T22:51:28+00:00 weekly 0.7 https://trial.medpath.com/news/matterhorn-trial-finds-teer-non-inferior-to-surgery-for-secondary-mitral-regurgitation 2024-09-01T22:02:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/matterhorn-trial-finds-teer-non-inferior-to-surgery-for-secondary-mitral-regurgitation 2024-09-01T22:02:08+00:00 weekly 0.7 https://trial.medpath.com/news/scoff-trial-confirms-that-fasting-is-not-needed-before-cath-lab-procedures 2024-09-01T21:19:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scoff-trial-confirms-that-fasting-is-not-needed-before-cath-lab-procedures 2024-09-01T21:19:29+00:00 weekly 0.7 https://trial.medpath.com/news/research-suggests-flexible-approach-to-antiplatelet-management-after-coronary-drug-eluting 2024-09-01T18:20:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-suggests-flexible-approach-to-antiplatelet-management-after-coronary-drug-eluting 2024-09-01T18:20:10+00:00 weekly 0.7 https://trial.medpath.com/news/irhythm-technologies-announces-results-of-guard-af-trial-globenewswire 2024-09-01T17:36:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irhythm-technologies-announces-results-of-guard-af-trial-globenewswire 2024-09-01T17:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/fentanyl-vaccine-created-in-texas-heads-for-clinical-trials-with-goal-of-saving-lives 2024-09-01T15:40:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fentanyl-vaccine-created-in-texas-heads-for-clinical-trials-with-goal-of-saving-lives 2024-09-01T15:40:30+00:00 weekly 0.7 https://trial.medpath.com/news/dr-chris-kramer-on-the-clinical-importance-of-finerenone-for-patients-with-heart-failure 2024-09-01T15:32:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-chris-kramer-on-the-clinical-importance-of-finerenone-for-patients-with-heart-failure 2024-09-01T15:32:27+00:00 weekly 0.7 https://trial.medpath.com/news/sglt2-inhibitor-empagliflozin-is-shown-to-be-safe-newswise 2024-09-01T14:09:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sglt2-inhibitor-empagliflozin-is-shown-to-be-safe-newswise 2024-09-01T14:09:20+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-ixekizumab-similarly-efficacious-in-challenging-body-areas-healio 2024-09-01T13:51:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/long-term-ixekizumab-similarly-efficacious-in-challenging-body-areas-healio 2024-09-01T13:51:27+00:00 weekly 0.7 https://trial.medpath.com/news/abata-therapeutics-treg-therapy-aba-101-garners-fda-fast-track-designation 2024-09-01T13:11:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abata-therapeutics-treg-therapy-aba-101-garners-fda-fast-track-designation 2024-09-01T13:11:27+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-good-news-for-advanced-cll-sll-with-bgb-16673-receiving-fast 2024-09-01T11:03:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-targeted-pulse-good-news-for-advanced-cll-sll-with-bgb-16673-receiving-fast 2024-09-01T11:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-presents-additional-data-from-sequoia-hcm-at-the-european-society-morningstar 2024-09-01T08:02:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cytokinetics-presents-additional-data-from-sequoia-hcm-at-the-european-society-morningstar 2024-09-01T08:02:50+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-reduces-risk-of-heart-failure-by-27pc-study-afr 2024-09-01T07:18:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-reduces-risk-of-heart-failure-by-27pc-study-afr 2024-09-01T07:18:34+00:00 weekly 0.7 https://trial.medpath.com/news/dedicated-trial-in-women-demonstrates-the-superiority-of-transcatheter-vs-surgical-aortic 2024-09-01T05:24:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dedicated-trial-in-women-demonstrates-the-superiority-of-transcatheter-vs-surgical-aortic 2024-09-01T05:24:26+00:00 weekly 0.7 https://trial.medpath.com/news/events-for-september-10-2024-rethinking-clinical-trials 2024-09-01T04:22:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/events-for-september-10-2024-rethinking-clinical-trials 2024-09-01T04:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/pause-or-keep-ras-inhibitors-before-surgery-take-your-pick-medpage-today 2024-09-01T04:13:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pause-or-keep-ras-inhibitors-before-surgery-take-your-pick-medpage-today 2024-09-01T04:13:40+00:00 weekly 0.7 https://trial.medpath.com/news/aggressive-supportive-care-following-novel-agents-may-reduce-infection 2024-09-01T03:58:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aggressive-supportive-care-following-novel-agents-may-reduce-infection 2024-09-01T03:58:30+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-to-new-drug-application-of-neurofibromatosis-agent-mirdametinib 2024-09-01T02:28:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-new-drug-application-of-neurofibromatosis-agent-mirdametinib 2024-09-01T02:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/novel-drug-development-advances-in-metastatic-colorectal-cancer-focus-on-kras-targeting-and-immunotherapy 2024-09-01T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-drug-development-advances-in-metastatic-colorectal-cancer-focus-on-kras-targeting-and-immunotherapy 2024-09-01T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-study-of-socazolimab-as-first-line-treatment-in-persistent-recurrent-or-metastatic-cervical-cancer 2024-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-study-of-socazolimab-as-first-line-treatment-in-persistent-recurrent-or-metastatic-cervical-cancer 2024-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/these-highlights-do-not-include-all-the-information-needed-to-use 2024-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/these-highlights-do-not-include-all-the-information-needed-to-use 2024-09-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/school-based-prevention-of-teacher-and-parental-violence-against-children-bmc-public-health 2024-08-31T23:34:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/school-based-prevention-of-teacher-and-parental-violence-against-children-bmc-public-health 2024-08-31T23:34:41+00:00 weekly 0.7 https://trial.medpath.com/news/nivolumab-plus-neoadjuvant-chemoradiation-fails-to-enhance-pcr-rate-in-esophageal 2024-08-31T22:02:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nivolumab-plus-neoadjuvant-chemoradiation-fails-to-enhance-pcr-rate-in-esophageal 2024-08-31T22:02:32+00:00 weekly 0.7 https://trial.medpath.com/news/oncolytic-peptide-vp-315-reduces-tumor-size-in-patients-with-basal-cell-carcinoma 2024-08-31T21:07:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oncolytic-peptide-vp-315-reduces-tumor-size-in-patients-with-basal-cell-carcinoma 2024-08-31T21:07:26+00:00 weekly 0.7 https://trial.medpath.com/news/esc-2024-study-highlights-potential-for-novartis-to-differentiate-in-hf-space 2024-08-31T18:42:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esc-2024-study-highlights-potential-for-novartis-to-differentiate-in-hf-space 2024-08-31T18:42:50+00:00 weekly 0.7 https://trial.medpath.com/news/esc-2024-sacubitril-valsartan-continues-to-impress-in-heart-failure-clinical-trials-arena 2024-08-31T18:10:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esc-2024-sacubitril-valsartan-continues-to-impress-in-heart-failure-clinical-trials-arena 2024-08-31T18:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/potassium-supplementation-and-prevention-of-atrial-fibrillation-after-cardiac-surgery 2024-08-31T16:21:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/potassium-supplementation-and-prevention-of-atrial-fibrillation-after-cardiac-surgery 2024-08-31T16:21:04+00:00 weekly 0.7 https://trial.medpath.com/news/a-clinical-trial-on-no-touch-vein-graft-in-coronary-surgery-swedegraft 2024-08-31T16:16:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-clinical-trial-on-no-touch-vein-graft-in-coronary-surgery-swedegraft 2024-08-31T16:16:43+00:00 weekly 0.7 https://trial.medpath.com/news/dr-dizman-on-future-efforts-to-elucidate-benefit-with-cbm588-in-first-line-rcc-onclive 2024-08-31T15:55:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-dizman-on-future-efforts-to-elucidate-benefit-with-cbm588-in-first-line-rcc-onclive 2024-08-31T15:55:38+00:00 weekly 0.7 https://trial.medpath.com/news/dr-dipti-itchhaporia-on-health-equity-clinical-trials-and-emerging-therapies-at-esc 2024-08-31T13:29:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-dipti-itchhaporia-on-health-equity-clinical-trials-and-emerging-therapies-at-esc 2024-08-31T13:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/the-promise-of-il-21-engineered-nk-cells-in-glioblastoma-treatment-targeted-oncology 2024-08-31T12:36:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-promise-of-il-21-engineered-nk-cells-in-glioblastoma-treatment-targeted-oncology 2024-08-31T12:36:23+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-priority-review-to-mirdametinib-for-nf1-associated-plexiform-neurofibromas 2024-08-31T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-priority-review-to-mirdametinib-for-nf1-associated-plexiform-neurofibromas 2024-08-31T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/more-drug-does-not-always-lead-to-more-efficacy-dr-mark-bleackley-on-the-progress-of 2024-08-31T11:41:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/more-drug-does-not-always-lead-to-more-efficacy-dr-mark-bleackley-on-the-progress-of 2024-08-31T11:41:57+00:00 weekly 0.7 https://trial.medpath.com/news/foundation-fighting-blindness-to-conduct-a-natural-history-study-of-usher-syndrome-type-3 2024-08-31T11:33:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/foundation-fighting-blindness-to-conduct-a-natural-history-study-of-usher-syndrome-type-3 2024-08-31T11:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/novel-low-dose-3-in-1-blood-pressure-pill-significantly-outperforms-standard-care-study-shows 2024-08-31T10:18:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-low-dose-3-in-1-blood-pressure-pill-significantly-outperforms-standard-care-study-shows 2024-08-31T10:18:26+00:00 weekly 0.7 https://trial.medpath.com/news/low-dose-triple-pill-vs-standard-care-protocols-for-hypertension-treatment-in-nigeria 2024-08-31T09:54:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-dose-triple-pill-vs-standard-care-protocols-for-hypertension-treatment-in-nigeria 2024-08-31T09:54:25+00:00 weekly 0.7 https://trial.medpath.com/news/abemaciclib-monotherapy-elicits-no-response-in-advanced-rcc-onclive 2024-08-31T08:10:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abemaciclib-monotherapy-elicits-no-response-in-advanced-rcc-onclive 2024-08-31T08:10:53+00:00 weekly 0.7 https://trial.medpath.com/news/esc-2024-obicetrapib-a-promising-breakthrough-for-dyslipidemia-treatment 2024-08-31T08:04:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esc-2024-obicetrapib-a-promising-breakthrough-for-dyslipidemia-treatment 2024-08-31T08:04:30+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-august-30-2024 2024-08-31T07:17:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cgtlive-r-s-weekly-rewind-august-30-2024 2024-08-31T07:17:34+00:00 weekly 0.7 https://trial.medpath.com/news/european-study-reveals-harmful-impact-of-delayed-myasthenia-gravis-diagnosis 2024-08-31T05:51:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-study-reveals-harmful-impact-of-delayed-myasthenia-gravis-diagnosis 2024-08-31T05:51:32+00:00 weekly 0.7 https://trial.medpath.com/news/nxp800-gains-fda-orphan-drug-status-in-arid1a-deficient-ovarian-cancers 2024-08-31T04:08:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nxp800-gains-fda-orphan-drug-status-in-arid1a-deficient-ovarian-cancers 2024-08-31T04:08:17+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-in-ireland-challenges-beliefs-about-ozempic-and-similar-new-obesity-treatments 2024-08-31T00:45:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-in-ireland-challenges-beliefs-about-ozempic-and-similar-new-obesity-treatments 2024-08-31T00:45:08+00:00 weekly 0.7 https://trial.medpath.com/news/esc-2024-select-trial-provides-promising-results-for-obesity-related-hfpef-treatment 2024-08-30T21:34:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esc-2024-select-trial-provides-promising-results-for-obesity-related-hfpef-treatment 2024-08-30T21:34:14+00:00 weekly 0.7 https://trial.medpath.com/news/phase-i-clinical-trial-of-nh130-and-the-prediction-of-its-pharmacokinetics-using-frontiers 2024-08-30T20:39:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-i-clinical-trial-of-nh130-and-the-prediction-of-its-pharmacokinetics-using-frontiers 2024-08-30T20:39:34+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-clinical-trial-commences-for-oral-myasthenia-gravis-treatment-healio 2024-08-30T18:54:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-clinical-trial-commences-for-oral-myasthenia-gravis-treatment-healio 2024-08-30T18:54:12+00:00 weekly 0.7 https://trial.medpath.com/news/cellprothera-inches-closer-to-phase-iii-trial-for-heart-attack-cell-therapy-clinical-trials-arena 2024-08-30T17:41:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cellprothera-inches-closer-to-phase-iii-trial-for-heart-attack-cell-therapy-clinical-trials-arena 2024-08-30T17:41:34+00:00 weekly 0.7 https://trial.medpath.com/news/orgenesis-car-t-org-101-demonstrates-efficacy-and-safety-in-acute-lymphoblastic 2024-08-30T17:14:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/orgenesis-car-t-org-101-demonstrates-efficacy-and-safety-in-acute-lymphoblastic 2024-08-30T17:14:39+00:00 weekly 0.7 https://trial.medpath.com/news/an-obesity-drug-prevents-covid-deaths-study-suggests-the-new-york-times 2024-08-30T17:08:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-obesity-drug-prevents-covid-deaths-study-suggests-the-new-york-times 2024-08-30T17:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/esc-2024-retatrutide-improves-lipid-and-cardiovascular-risk-profile-in-phase-ii-trial 2024-08-30T16:44:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esc-2024-retatrutide-improves-lipid-and-cardiovascular-risk-profile-in-phase-ii-trial 2024-08-30T16:44:42+00:00 weekly 0.7 https://trial.medpath.com/news/mother-frantic-to-save-clinical-trial-that-could-cure-her-daughter-the-treatment-is-sitting-in-a-fridge 2024-08-30T16:37:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mother-frantic-to-save-clinical-trial-that-could-cure-her-daughter-the-treatment-is-sitting-in-a-fridge 2024-08-30T16:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/abyss-trial-no-difference-in-outcomes-continuing-or-stopping-beta-blockers-following-mi 2024-08-30T16:30:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abyss-trial-no-difference-in-outcomes-continuing-or-stopping-beta-blockers-following-mi 2024-08-30T16:30:50+00:00 weekly 0.7 https://trial.medpath.com/news/nih-grants-funds-to-establish-network-for-nursing-home-trials 2024-08-30T15:15:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-grants-funds-to-establish-network-for-nursing-home-trials 2024-08-30T15:15:21+00:00 weekly 0.7 https://trial.medpath.com/news/benefits-of-dark-chocolate-intake-on-retinal-vessels-functionality-nature 2024-08-30T14:58:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/benefits-of-dark-chocolate-intake-on-retinal-vessels-functionality-nature 2024-08-30T14:58:18+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-wegovy-have-health-benefits-beyond-weight-loss-studies-find 2024-08-30T14:08:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-wegovy-have-health-benefits-beyond-weight-loss-studies-find 2024-08-30T14:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/australian-first-clinical-trial-of-personalised-immunotherapy-used-on-two-perth-cancer-patients-abc 2024-08-30T13:48:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/australian-first-clinical-trial-of-personalised-immunotherapy-used-on-two-perth-cancer-patients-abc 2024-08-30T13:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/an-oral-small-molecule-pcsk9-inhibitor-disclosed-by-astrazeneca 2024-08-30T13:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-oral-small-molecule-pcsk9-inhibitor-disclosed-by-astrazeneca 2024-08-30T13:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/leading-cardiologist-deepak-bhatt-highlights-critical-challenges-in-clinical-trial-interpretation 2024-08-30T11:17:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leading-cardiologist-deepak-bhatt-highlights-critical-challenges-in-clinical-trial-interpretation 2024-08-30T11:17:25+00:00 weekly 0.7 https://trial.medpath.com/news/community-oncologists-face-growing-decision-support-crisis-amid-cancer-care-complexity 2024-08-30T10:00:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/community-oncologists-face-growing-decision-support-crisis-amid-cancer-care-complexity 2024-08-30T10:00:02+00:00 weekly 0.7 https://trial.medpath.com/news/us-leads-global-cancer-vaccine-research-with-47-of-clinical-trials 2024-08-30T08:12:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-leads-global-cancer-vaccine-research-with-47-of-clinical-trials 2024-08-30T08:12:50+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-diversity-gap-costs-healthcare-system-11-trillion-nasem-report-reveals 2024-08-30T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-diversity-gap-costs-healthcare-system-11-trillion-nasem-report-reveals 2024-08-30T07:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-pooled-analysis-published-in-the-lancet-demonstrated-reduced-risk-of-combined-cv-death-or-worsening-heart-failure-with-semaglutide 2024-08-30T03:09:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-pooled-analysis-published-in-the-lancet-demonstrated-reduced-risk-of-combined-cv-death-or-worsening-heart-failure-with-semaglutide 2024-08-30T03:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-ink-unveils-edcxtra-integrated-data-capture-platform-to-streamline-clinical-trials 2024-08-30T02:27:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-ink-unveils-edcxtra-integrated-data-capture-platform-to-streamline-clinical-trials 2024-08-30T02:27:33+00:00 weekly 0.7 https://trial.medpath.com/news/and-medium-term-outcomes-of-novel-biologics-and-lightweight-synthetic-mesh-for-pubmed 2024-08-30T00:32:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/and-medium-term-outcomes-of-novel-biologics-and-lightweight-synthetic-mesh-for-pubmed 2024-08-30T00:32:26+00:00 weekly 0.7 https://trial.medpath.com/news/novavax-2024-2025-formula-covid-19-vaccine-now-authorized-and-recommended-for-use-in-the-u-s 2024-08-30T00:08:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novavax-2024-2025-formula-covid-19-vaccine-now-authorized-and-recommended-for-use-in-the-u-s 2024-08-30T00:08:42+00:00 weekly 0.7 https://trial.medpath.com/news/aclarion-launches-second-clinical-utility-and-economic-clue-trial-site-with-first 2024-08-29T23:46:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aclarion-launches-second-clinical-utility-and-economic-clue-trial-site-with-first 2024-08-29T23:46:48+00:00 weekly 0.7 https://trial.medpath.com/news/arizona-bioscience-news-u-of-a-president-salary-journey-venture-studio-ivy-brian-center 2024-08-29T23:29:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arizona-bioscience-news-u-of-a-president-salary-journey-venture-studio-ivy-brian-center 2024-08-29T23:29:19+00:00 weekly 0.7 https://trial.medpath.com/news/inari-medical-announces-peerless-data-to-be-presented-during-the-late-breaking-morningstar 2024-08-29T20:28:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inari-medical-announces-peerless-data-to-be-presented-during-the-late-breaking-morningstar 2024-08-29T20:28:50+00:00 weekly 0.7 https://trial.medpath.com/news/four-new-clinical-trials-grants-from-the-cihr-for-ri-muhc-researchers-health-e-news 2024-08-29T19:36:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/four-new-clinical-trials-grants-from-the-cihr-for-ri-muhc-researchers-health-e-news 2024-08-29T19:36:42+00:00 weekly 0.7 https://trial.medpath.com/news/dr-hantel-on-eligibility-criteria-associated-with-racial-ethnic-disparities-in-clinical-trial 2024-08-29T19:22:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-hantel-on-eligibility-criteria-associated-with-racial-ethnic-disparities-in-clinical-trial 2024-08-29T19:22:54+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-ensitrelvir-for-asymptomatic-or-mild-covid-19-an-exploratory 2024-08-29T19:12:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/efficacy-and-safety-of-ensitrelvir-for-asymptomatic-or-mild-covid-19-an-exploratory 2024-08-29T19:12:48+00:00 weekly 0.7 https://trial.medpath.com/news/health-matters-mental-health-edition-methamphetamine-addiction-a-larc-clinical-trial 2024-08-29T18:22:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/health-matters-mental-health-edition-methamphetamine-addiction-a-larc-clinical-trial 2024-08-29T18:22:18+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-attempt-to-emulate-a-clinical-trial-using-data-from-real-patients-medical-xpress 2024-08-29T18:03:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-attempt-to-emulate-a-clinical-trial-using-data-from-real-patients-medical-xpress 2024-08-29T18:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-tackles-clinical-trial-diversity-is-congress-next-national-health-council 2024-08-29T17:47:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-tackles-clinical-trial-diversity-is-congress-next-national-health-council 2024-08-29T17:47:39+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-aims-to-test-tolerability-of-felodipine-in-hd-rare-disease-advisor 2024-08-29T17:36:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-aims-to-test-tolerability-of-felodipine-in-hd-rare-disease-advisor 2024-08-29T17:36:49+00:00 weekly 0.7 https://trial.medpath.com/news/keytruda-fails-lung-and-skin-cancer-trials-limiting-further-expansion-biopharma-dive 2024-08-29T16:53:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keytruda-fails-lung-and-skin-cancer-trials-limiting-further-expansion-biopharma-dive 2024-08-29T16:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/merck-provides-update-on-phase-3-keynote-867-and-keynote-630-trials-merck-com 2024-08-29T16:46:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-provides-update-on-phase-3-keynote-867-and-keynote-630-trials-merck-com 2024-08-29T16:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/ireland-steps-up-efforts-to-boost-clinical-trial-performance-by-standardizing-ctas 2024-08-29T16:07:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ireland-steps-up-efforts-to-boost-clinical-trial-performance-by-standardizing-ctas 2024-08-29T16:07:49+00:00 weekly 0.7 https://trial.medpath.com/news/nih-r01-grant-awarded-to-dr-vajravelu-for-novel-clinical-trial 2024-08-29T16:04:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-r01-grant-awarded-to-dr-vajravelu-for-novel-clinical-trial 2024-08-29T16:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/cambridgeshire-boy-takes-part-in-brain-tumour-drug-trial-cambridge-children-s 2024-08-29T15:00:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cambridgeshire-boy-takes-part-in-brain-tumour-drug-trial-cambridge-children-s 2024-08-29T15:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-fails-phase-3-trial-in-japan-bat-set-to-see-growth-from-cannabis-investment 2024-08-29T14:42:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jazz-fails-phase-3-trial-in-japan-bat-set-to-see-growth-from-cannabis-investment 2024-08-29T14:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-assesses-the-efficacy-of-suvorexant-in-reducing-delirium-in-older-adults 2024-08-29T14:34:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-assesses-the-efficacy-of-suvorexant-in-reducing-delirium-in-older-adults 2024-08-29T14:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/neura-launches-world-s-largest-clinical-trial-for-phantom-limb-pain-news-hub 2024-08-29T14:09:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neura-launches-world-s-largest-clinical-trial-for-phantom-limb-pain-news-hub 2024-08-29T14:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/melodi-health-announces-10-75-million-in-series-a-funding-first-enrollment-in-pivotal-clinical-trial 2024-08-29T13:16:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/melodi-health-announces-10-75-million-in-series-a-funding-first-enrollment-in-pivotal-clinical-trial 2024-08-29T13:16:22+00:00 weekly 0.7 https://trial.medpath.com/news/mindbio-ceo-provides-video-update-to-shareholders-on-progress-of-world-first-thenewswire 2024-08-29T13:05:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mindbio-ceo-provides-video-update-to-shareholders-on-progress-of-world-first-thenewswire 2024-08-29T13:05:45+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-wclc-and-esmo-2024 2024-08-29T11:59:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-wclc-and-esmo-2024 2024-08-29T11:59:34+00:00 weekly 0.7 https://trial.medpath.com/news/neurocrine-reports-positive-data-from-phase-ii-schizophrenia-treatment-trial 2024-08-29T11:43:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurocrine-reports-positive-data-from-phase-ii-schizophrenia-treatment-trial 2024-08-29T11:43:16+00:00 weekly 0.7 https://trial.medpath.com/news/gain-therapeutics-announces-positive-topline-results-from-the-phase-1-clinical-trial-of-gt 2024-08-29T11:40:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gain-therapeutics-announces-positive-topline-results-from-the-phase-1-clinical-trial-of-gt 2024-08-29T11:40:46+00:00 weekly 0.7 https://trial.medpath.com/news/don-t-delay-covid-19-booster-vaccination-study-reveals-doherty-website 2024-08-29T10:21:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/don-t-delay-covid-19-booster-vaccination-study-reveals-doherty-website 2024-08-29T10:21:57+00:00 weekly 0.7 https://trial.medpath.com/news/migraine-drug-ubrelvy-may-stop-headaches-before-they-start 2024-08-29T10:08:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/migraine-drug-ubrelvy-may-stop-headaches-before-they-start 2024-08-29T10:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/repare-therapeutics-announces-strategic-reprioritization-to-focus-on-broad-clinical-portfolio 2024-08-29T10:04:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/repare-therapeutics-announces-strategic-reprioritization-to-focus-on-broad-clinical-portfolio 2024-08-29T10:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/offering-peace-of-mind-peanut-immunotherapy-clinical-trials-at-lurie-children-s-eurekalert 2024-08-29T08:15:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/offering-peace-of-mind-peanut-immunotherapy-clinical-trials-at-lurie-children-s-eurekalert 2024-08-29T08:15:26+00:00 weekly 0.7 https://trial.medpath.com/news/transcenta-holding-limited-stock-code-6628-hk-announce-2024-interim-results 2024-08-29T07:54:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transcenta-holding-limited-stock-code-6628-hk-announce-2024-interim-results 2024-08-29T07:54:59+00:00 weekly 0.7 https://trial.medpath.com/news/around-the-helix-cell-and-gene-therapy-company-updates-august-28-2024-cgtlive-r 2024-08-29T07:17:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/around-the-helix-cell-and-gene-therapy-company-updates-august-28-2024-cgtlive-r 2024-08-29T07:17:22+00:00 weekly 0.7 https://trial.medpath.com/news/human-papillomavirus-hpv-trials-a-cross-sectional-analysis-of-clinical-trials-registries-pubmed 2024-08-29T04:59:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/human-papillomavirus-hpv-trials-a-cross-sectional-analysis-of-clinical-trials-registries-pubmed 2024-08-29T04:59:18+00:00 weekly 0.7 https://trial.medpath.com/news/emergent-biosolutions-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-receives-u-s-fda-approval-for-mpox-indication 2024-08-29T04:08:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emergent-biosolutions-acam2000-smallpox-and-mpox-vaccinia-vaccine-live-receives-u-s-fda-approval-for-mpox-indication 2024-08-29T04:08:02+00:00 weekly 0.7 https://trial.medpath.com/news/umass-chan-scientist-shan-lu-reports-on-effectiveness-of-dna-vaccine-to-prevent-hiv 2024-08-29T04:06:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/umass-chan-scientist-shan-lu-reports-on-effectiveness-of-dna-vaccine-to-prevent-hiv 2024-08-29T04:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/randomized-controlled-trial-assessing-vitamin-d-s-role-in-reducing-bppv-recurrence-pubmed 2024-08-29T00:47:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/randomized-controlled-trial-assessing-vitamin-d-s-role-in-reducing-bppv-recurrence-pubmed 2024-08-29T00:47:01+00:00 weekly 0.7 https://trial.medpath.com/news/qlife-holding-ab-interim-report-q2-april-to-june-2024 2024-08-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qlife-holding-ab-interim-report-q2-april-to-june-2024 2024-08-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-guard-therapeutics-phase-2b-study-pointer 2024-08-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patient-dosed-in-guard-therapeutics-phase-2b-study-pointer 2024-08-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/expert-reaction-to-observational-study-claiming-certain-diabetes-drugs-might-prevent-dementia 2024-08-28T22:59:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-reaction-to-observational-study-claiming-certain-diabetes-drugs-might-prevent-dementia 2024-08-28T22:59:29+00:00 weekly 0.7 https://trial.medpath.com/news/university-of-utah-health-participates-in-groundbreaking-pain-management-research-study 2024-08-28T20:04:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/university-of-utah-health-participates-in-groundbreaking-pain-management-research-study 2024-08-28T20:04:50+00:00 weekly 0.7 https://trial.medpath.com/news/estimating-cure-proportion-in-cancer-clinical-trials-using-flexible-parametric-cure-models 2024-08-28T19:49:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/estimating-cure-proportion-in-cancer-clinical-trials-using-flexible-parametric-cure-models 2024-08-28T19:49:56+00:00 weekly 0.7 https://trial.medpath.com/news/gatc-mci-team-on-ai-clinical-trial-funding-and-insurance-model-informa-connect 2024-08-28T19:40:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gatc-mci-team-on-ai-clinical-trial-funding-and-insurance-model-informa-connect 2024-08-28T19:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/participant-visits-complete-in-phase-2b-trial-of-cls-ax-for-wet-amd-healio 2024-08-28T19:37:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/participant-visits-complete-in-phase-2b-trial-of-cls-ax-for-wet-amd-healio 2024-08-28T19:37:43+00:00 weekly 0.7 https://trial.medpath.com/news/news-dosing-underway-in-world-s-first-in-vivo-crispr-trial-for-primary-hyperoxaluria 2024-08-28T19:13:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/news-dosing-underway-in-world-s-first-in-vivo-crispr-trial-for-primary-hyperoxaluria 2024-08-28T19:13:17+00:00 weekly 0.7 https://trial.medpath.com/news/verve-therapeutics-investor-sues-over-clinical-trial-stoppage-bloomberg-law-news 2024-08-28T18:36:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verve-therapeutics-investor-sues-over-clinical-trial-stoppage-bloomberg-law-news 2024-08-28T18:36:51+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-trial-of-her-vaxx-a-b-cell-peptide-based-vaccine-in-her2-overexpressing 2024-08-28T17:45:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-ii-trial-of-her-vaxx-a-b-cell-peptide-based-vaccine-in-her2-overexpressing 2024-08-28T17:45:49+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-therapies-a-new-frontier-in-mash-treatment-clinical-trials-arena 2024-08-28T17:16:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-therapies-a-new-frontier-in-mash-treatment-clinical-trials-arena 2024-08-28T17:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/optimi-health-atma-receive-no-objection-letter-from-health-canada-for-phase-2-clinical-trial 2024-08-28T16:29:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/optimi-health-atma-receive-no-objection-letter-from-health-canada-for-phase-2-clinical-trial 2024-08-28T16:29:49+00:00 weekly 0.7 https://trial.medpath.com/news/uk-secures-ps400-million-investment-to-boost-clinical-trials-gov-uk 2024-08-28T16:09:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/uk-secures-ps400-million-investment-to-boost-clinical-trials-gov-uk 2024-08-28T16:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/new-brain-tumor-drug-hits-market-16-years-after-duke-neurosurgeon-s-discovery-abc11 2024-08-28T15:55:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-brain-tumor-drug-hits-market-16-years-after-duke-neurosurgeon-s-discovery-abc11 2024-08-28T15:55:53+00:00 weekly 0.7 https://trial.medpath.com/news/promising-mpox-drug-fails-in-trials-as-virus-spreads-wired 2024-08-28T15:37:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-mpox-drug-fails-in-trials-as-virus-spreads-wired 2024-08-28T15:37:18+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-expands-u-s-clinical-sites-for-relapsed-refractory-al-amyloidosis-trial 2024-08-28T14:08:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immix-biopharma-expands-u-s-clinical-sites-for-relapsed-refractory-al-amyloidosis-trial 2024-08-28T14:08:12+00:00 weekly 0.7 https://trial.medpath.com/news/emvenio-s-clinical-research-sites-at-prime-healthcare-hospitals-now-open-in-dallas-and-atlanta 2024-08-28T14:06:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/emvenio-s-clinical-research-sites-at-prime-healthcare-hospitals-now-open-in-dallas-and-atlanta 2024-08-28T14:06:43+00:00 weekly 0.7 https://trial.medpath.com/news/notable-uh-and-cwru-clinician-researcher-and-educator-robert-salata-md-facp 2024-08-28T14:06:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/notable-uh-and-cwru-clinician-researcher-and-educator-robert-salata-md-facp 2024-08-28T14:06:41+00:00 weekly 0.7 https://trial.medpath.com/news/hyundai-bioscience-to-conduct-phase-3-clinical-trial-for-high-risk-group-of-covid-19-patients 2024-08-28T13:37:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hyundai-bioscience-to-conduct-phase-3-clinical-trial-for-high-risk-group-of-covid-19-patients 2024-08-28T13:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-twice-yearly-leqvio-r-demonstrated-clinically-meaningful-statistically-significant 2024-08-28T13:06:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-twice-yearly-leqvio-r-demonstrated-clinically-meaningful-statistically-significant 2024-08-28T13:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/game-changer-take-home-blood-cancer-drug-to-be-offered-by-nhs-england 2024-08-28T12:33:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/game-changer-take-home-blood-cancer-drug-to-be-offered-by-nhs-england 2024-08-28T12:33:04+00:00 weekly 0.7 https://trial.medpath.com/news/experts-call-for-technology-driven-solutions-to-boost-minority-representation-in-cll-clinical-trials 2024-08-28T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/experts-call-for-technology-driven-solutions-to-boost-minority-representation-in-cll-clinical-trials 2024-08-28T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/leading-experts-to-host-webinar-on-scientific-storytelling-in-medical-publications 2024-08-28T07:30:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leading-experts-to-host-webinar-on-scientific-storytelling-in-medical-publications 2024-08-28T07:30:48+00:00 weekly 0.7 https://trial.medpath.com/news/crf-announces-tct-2024-late-breaking-clinical-trials-and-science 2024-08-28T07:20:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/crf-announces-tct-2024-late-breaking-clinical-trials-and-science 2024-08-28T07:20:38+00:00 weekly 0.7 https://trial.medpath.com/news/wanted-t1d-participants-for-clinical-trial-to-test-semaglutide-jdrf-australia 2024-08-28T06:52:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wanted-t1d-participants-for-clinical-trial-to-test-semaglutide-jdrf-australia 2024-08-28T06:52:31+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-taking-place-in-houston-for-those-who-want-to-stop-smoking-lose-weight 2024-08-28T03:30:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-taking-place-in-houston-for-those-who-want-to-stop-smoking-lose-weight 2024-08-28T03:30:26+00:00 weekly 0.7 https://trial.medpath.com/news/telix-submits-nda-for-tlx101-cdx-pixclara-brain-cancer-imaging-agent 2024-08-28T03:08:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/telix-submits-nda-for-tlx101-cdx-pixclara-brain-cancer-imaging-agent 2024-08-28T03:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/trailblazers-in-innovation-medical-college-of-wisconsin 2024-08-28T02:36:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trailblazers-in-innovation-medical-college-of-wisconsin 2024-08-28T02:36:56+00:00 weekly 0.7 https://trial.medpath.com/news/waiver-of-local-clinical-trial-requirements-by-csdso-a-well-deliberated-move-shweta-rai 2024-08-28T02:31:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/waiver-of-local-clinical-trial-requirements-by-csdso-a-well-deliberated-move-shweta-rai 2024-08-28T02:31:03+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-introduces-lower-cost-single-dose-zepbound-vials-to-expand-obesity-treatment-access 2024-08-28T00:49:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-introduces-lower-cost-single-dose-zepbound-vials-to-expand-obesity-treatment-access 2024-08-28T00:49:26+00:00 weekly 0.7 https://trial.medpath.com/news/i-mab-reports-1h-2024-financial-results-pipeline-progress-and 2024-08-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-mab-reports-1h-2024-financial-results-pipeline-progress-and 2024-08-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eshunt-r-system-receives-fda-breakthrough-device-designation 2024-08-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eshunt-r-system-receives-fda-breakthrough-device-designation 2024-08-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/european-commission-approves-astellas-padcev-tm-enfortumab-vedotin-in 2024-08-27T23:34:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-commission-approves-astellas-padcev-tm-enfortumab-vedotin-in 2024-08-27T23:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/nebulized-enriched-heparin-improves-respiratory-parameters-in-patients-with-covid-19 2024-08-27T22:47:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nebulized-enriched-heparin-improves-respiratory-parameters-in-patients-with-covid-19 2024-08-27T22:47:51+00:00 weekly 0.7 https://trial.medpath.com/news/projenx-announces-formation-of-clinical-advisory-board-pr-newswire 2024-08-27T21:10:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/projenx-announces-formation-of-clinical-advisory-board-pr-newswire 2024-08-27T21:10:22+00:00 weekly 0.7 https://trial.medpath.com/news/investigating-immune-tolerance-in-celiac-disease-avalon-clinical-trial 2024-08-27T20:05:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/investigating-immune-tolerance-in-celiac-disease-avalon-clinical-trial 2024-08-27T20:05:11+00:00 weekly 0.7 https://trial.medpath.com/news/next-level-breast-reconstruction-after-cancer-university-of-houston 2024-08-27T19:48:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/next-level-breast-reconstruction-after-cancer-university-of-houston 2024-08-27T19:48:35+00:00 weekly 0.7 https://trial.medpath.com/news/limited-impact-of-cannabidiol-on-health-related-quality-of-life-of-people-with-long-term-controlled-hiv 2024-08-27T19:37:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/limited-impact-of-cannabidiol-on-health-related-quality-of-life-of-people-with-long-term-controlled-hiv 2024-08-27T19:37:55+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-dosing-complete-in-phase-1-trial-of-aiv007-for-amd-diabetic-macular-edema 2024-08-27T19:11:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enrollment-dosing-complete-in-phase-1-trial-of-aiv007-for-amd-diabetic-macular-edema 2024-08-27T19:11:06+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-registers-clinical-trial-on-wegovy-s-long-term-effects-on-teens-quartz 2024-08-27T18:41:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-registers-clinical-trial-on-wegovy-s-long-term-effects-on-teens-quartz 2024-08-27T18:41:22+00:00 weekly 0.7 https://trial.medpath.com/news/jw-therapeutics-relma-cell-approved-in-china-for-r-r-mantle-cell-lymphoma 2024-08-27T18:22:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jw-therapeutics-relma-cell-approved-in-china-for-r-r-mantle-cell-lymphoma 2024-08-27T18:22:25+00:00 weekly 0.7 https://trial.medpath.com/news/xlhed-clinical-trial-opens-new-site-in-los-angeles 2024-08-27T17:26:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xlhed-clinical-trial-opens-new-site-in-los-angeles 2024-08-27T17:26:46+00:00 weekly 0.7 https://trial.medpath.com/news/thoracic-oncology-program-research-ucsf 2024-08-27T16:43:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/thoracic-oncology-program-research-ucsf 2024-08-27T16:43:55+00:00 weekly 0.7 https://trial.medpath.com/news/new-insights-on-brain-spinal-communication-in-opioid-withdrawal-lead-to-a-clinical-trial 2024-08-27T16:32:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-insights-on-brain-spinal-communication-in-opioid-withdrawal-lead-to-a-clinical-trial 2024-08-27T16:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-engineered-cell-therapy-for-advanced-synovial-sarcoma-national-cancer-institute 2024-08-27T16:26:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-engineered-cell-therapy-for-advanced-synovial-sarcoma-national-cancer-institute 2024-08-27T16:26:41+00:00 weekly 0.7 https://trial.medpath.com/news/covid-19-nasal-vaccine-ready-for-clinical-trials-inside-precision-medicine 2024-08-27T15:18:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/covid-19-nasal-vaccine-ready-for-clinical-trials-inside-precision-medicine 2024-08-27T15:18:54+00:00 weekly 0.7 https://trial.medpath.com/news/harvard-apparatus-regenerative-technology-secures-5m-to-continue-clinical-trial 2024-08-27T14:57:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/harvard-apparatus-regenerative-technology-secures-5m-to-continue-clinical-trial 2024-08-27T14:57:01+00:00 weekly 0.7 https://trial.medpath.com/news/oculis-closes-phase-iii-eye-drop-trial-due-to-third-party-administrative-error-biospace 2024-08-27T14:50:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oculis-closes-phase-iii-eye-drop-trial-due-to-third-party-administrative-error-biospace 2024-08-27T14:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/atlantic-veterinary-college-initiates-clinical-trial-for-treatment-of-cardiac-tumours-in-dogs 2024-08-27T14:41:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atlantic-veterinary-college-initiates-clinical-trial-for-treatment-of-cardiac-tumours-in-dogs 2024-08-27T14:41:17+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-for-first-lung-cancer-vaccine-underway-where-in-va-and-md-is-it-being-tested 2024-08-27T13:05:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-for-first-lung-cancer-vaccine-underway-where-in-va-and-md-is-it-being-tested 2024-08-27T13:05:04+00:00 weekly 0.7 https://trial.medpath.com/news/astellas-initiates-phase-3-clinical-study-of-fezolinetant-for-vms-in-women-with-breast 2024-08-27T13:04:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astellas-initiates-phase-3-clinical-study-of-fezolinetant-for-vms-in-women-with-breast 2024-08-27T13:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/mabwell-receives-approval-for-phase-iii-trial-of-urothelial-carcinoma-drug-in-china 2024-08-27T12:34:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mabwell-receives-approval-for-phase-iii-trial-of-urothelial-carcinoma-drug-in-china 2024-08-27T12:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-first-automated-device-to-deliver-insulin-to-people-with-type-2-diabetes 2024-08-27T12:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-first-automated-device-to-deliver-insulin-to-people-with-type-2-diabetes 2024-08-27T12:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/diakonos-oncology-secures-funds-for-phase-ii-trial-of-dendritic-cell-vaccine 2024-08-27T11:39:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/diakonos-oncology-secures-funds-for-phase-ii-trial-of-dendritic-cell-vaccine 2024-08-27T11:39:32+00:00 weekly 0.7 https://trial.medpath.com/news/gi-innovation-and-msd-partner-for-trial-of-gi-102-and-keytruda-regimen-for-cancer 2024-08-27T11:39:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gi-innovation-and-msd-partner-for-trial-of-gi-102-and-keytruda-regimen-for-cancer 2024-08-27T11:39:32+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-phase-3-trial-initiation-for-bomedemstat-an-investigational-candidate-for 2024-08-27T10:50:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-announces-phase-3-trial-initiation-for-bomedemstat-an-investigational-candidate-for 2024-08-27T10:50:51+00:00 weekly 0.7 https://trial.medpath.com/news/opna-bio-doses-first-subject-in-phase-i-trial-of-treatment-for-multiple-myeloma 2024-08-27T10:03:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/opna-bio-doses-first-subject-in-phase-i-trial-of-treatment-for-multiple-myeloma 2024-08-27T10:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/omny-ire-clinical-trial-completes-enrolment-cardiac-rhythm-news 2024-08-27T09:03:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/omny-ire-clinical-trial-completes-enrolment-cardiac-rhythm-news 2024-08-27T09:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/microbiotica-doses-first-patient-in-phase-1b-trial-of-mb097-microbiome-therapy-for-advanced-melanoma 2024-08-27T09:00:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/microbiotica-doses-first-patient-in-phase-1b-trial-of-mb097-microbiome-therapy-for-advanced-melanoma 2024-08-27T09:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/vaderis-announces-positive-clinical-proof-of-concept-trial-in-hht-morningstar 2024-08-27T07:48:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vaderis-announces-positive-clinical-proof-of-concept-trial-in-hht-morningstar 2024-08-27T07:48:32+00:00 weekly 0.7 https://trial.medpath.com/news/c-difficile-vaccine-candidate-fails-to-meet-primary-end-point-in-phase-3-trial-cidrap 2024-08-27T07:35:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/c-difficile-vaccine-candidate-fails-to-meet-primary-end-point-in-phase-3-trial-cidrap 2024-08-27T07:35:28+00:00 weekly 0.7 https://trial.medpath.com/news/unm-launches-clinical-trial-using-heated-chemo-for-ovarian-cancer-new-mexico-sun 2024-08-27T06:53:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unm-launches-clinical-trial-using-heated-chemo-for-ovarian-cancer-new-mexico-sun 2024-08-27T06:53:06+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-in-phoenix-offering-hope-for-brain-cancer-patients-azfamily 2024-08-27T06:16:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-in-phoenix-offering-hope-for-brain-cancer-patients-azfamily 2024-08-27T06:16:48+00:00 weekly 0.7 https://trial.medpath.com/news/mytomorrows-and-pancreatic-cancer-europe-unite-to-enhance-clinical-trial-access-across-europe 2024-08-27T05:26:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mytomorrows-and-pancreatic-cancer-europe-unite-to-enhance-clinical-trial-access-across-europe 2024-08-27T05:26:43+00:00 weekly 0.7 https://trial.medpath.com/news/soleno-therapeutics-announces-u-s-fda-acceptance-for-filing-and-priority-review-of-nda-for-dccr-diazoxide-choline-extended-release-tablets-in-prader-willi-syndrome 2024-08-27T05:08:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/soleno-therapeutics-announces-u-s-fda-acceptance-for-filing-and-priority-review-of-nda-for-dccr-diazoxide-choline-extended-release-tablets-in-prader-willi-syndrome 2024-08-27T05:08:33+00:00 weekly 0.7 https://trial.medpath.com/news/walgreens-and-barda-enter-partnership-to-progress-decentralized-clinical-research-program 2024-08-27T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/walgreens-and-barda-enter-partnership-to-progress-decentralized-clinical-research-program 2024-08-27T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/news/par-24-274-nci-research-specialist-clinician-scientist-award-r50-clinical-trial-not-allowed 2024-08-27T04:56:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/par-24-274-nci-research-specialist-clinician-scientist-award-r50-clinical-trial-not-allowed 2024-08-27T04:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/intermittent-energy-restriction-for-adolescents-with-obesity-the-fast-track-to-health 2024-08-27T00:09:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intermittent-energy-restriction-for-adolescents-with-obesity-the-fast-track-to-health 2024-08-27T00:09:19+00:00 weekly 0.7 https://trial.medpath.com/news/low-intensity-blood-stem-cell-transplants-for-sickle-cell-appear-safe-for-lung-health 2024-08-27T00:08:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/low-intensity-blood-stem-cell-transplants-for-sickle-cell-appear-safe-for-lung-health 2024-08-27T00:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-is-transforming-solid-tumor-cancer-outcomes-with 2024-08-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/johnson-johnson-is-transforming-solid-tumor-cancer-outcomes-with 2024-08-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-releases-important-information-about-risk-of-covid-19-due-to-sars-cov-2-viral-variants-with-substantially-reduced-susceptibility-to-pemgarda-pemivibart 2024-08-26T23:08:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-releases-important-information-about-risk-of-covid-19-due-to-sars-cov-2-viral-variants-with-substantially-reduced-susceptibility-to-pemgarda-pemivibart 2024-08-26T23:08:08+00:00 weekly 0.7 https://trial.medpath.com/news/new-approach-helps-more-people-with-rectal-cancers-avoid-surgery 2024-08-26T09:08:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-approach-helps-more-people-with-rectal-cancers-avoid-surgery 2024-08-26T09:08:30+00:00 weekly 0.7 https://trial.medpath.com/news/an-alzheimer-s-drug-may-also-slow-lewy-body-dementia 2024-08-26T09:08:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-alzheimer-s-drug-may-also-slow-lewy-body-dementia 2024-08-26T09:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/mckesson-acquires-2-49-billion-controlling-stake-in-florida-cancer-specialists-to-expand-community-oncology-platform 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mckesson-acquires-2-49-billion-controlling-stake-in-florida-cancer-specialists-to-expand-community-oncology-platform 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rhythm-pharmaceuticals-announces-fda-acceptance-for-globenewswire 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rhythm-pharmaceuticals-announces-fda-acceptance-for-globenewswire 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/celltrion-s-steqeyma-gets-ec-approval-for-inflammatory-diseases 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/celltrion-s-steqeyma-gets-ec-approval-for-inflammatory-diseases 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/si-bone-sibn-receives-fda-nod-for-its-tnt-implant-system 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/si-bone-sibn-receives-fda-nod-for-its-tnt-implant-system 2024-08-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/xaluritamig-a-promising-new-therapeutic-for-metastatic-castration-resistant-prostate-cancer 2024-08-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xaluritamig-a-promising-new-therapeutic-for-metastatic-castration-resistant-prostate-cancer 2024-08-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/izotropic-plans-regulatory-approval-for-izoview-breast-ct-in-u-s-and-eu 2024-08-23T13:46:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/izotropic-plans-regulatory-approval-for-izoview-breast-ct-in-u-s-and-eu 2024-08-23T13:46:57+00:00 weekly 0.7 https://trial.medpath.com/news/wegovy-helps-patients-with-heart-failure-avoid-heart-attack-stroke 2024-08-23T09:08:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wegovy-helps-patients-with-heart-failure-avoid-heart-attack-stroke 2024-08-23T09:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/no-link-found-between-migraines-parkinson-s-disease 2024-08-23T09:08:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/no-link-found-between-migraines-parkinson-s-disease 2024-08-23T09:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/lixte-biotechnology-faces-nasdaq-delisting-over-equity 2024-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lixte-biotechnology-faces-nasdaq-delisting-over-equity 2024-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mrna-cancer-vaccine-clinical-trials-insight 2024-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mrna-cancer-vaccine-clinical-trials-insight 2024-08-23T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/the-journal-of-american-medical-association-jama-publishes-elinzanetant-phase-iii-data 2024-08-22T22:08:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/the-journal-of-american-medical-association-jama-publishes-elinzanetant-phase-iii-data 2024-08-22T22:08:53+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-receives-u-s-fda-approval-for-updated-covid-19-vaccine-targeting-kp-2-variant-of-sars-cov-2 2024-08-22T22:08:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moderna-receives-u-s-fda-approval-for-updated-covid-19-vaccine-targeting-kp-2-variant-of-sars-cov-2 2024-08-22T22:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-initiates-phase-ii-study-of-soluble-guanylate-cyclase-activator-bay3283142-in-patients-with-chronic-kidney-disease 2024-08-22T22:08:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-initiates-phase-ii-study-of-soluble-guanylate-cyclase-activator-bay3283142-in-patients-with-chronic-kidney-disease 2024-08-22T22:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/nice-rejects-alzheimer-s-drug-lecanemab-despite-mhra-approval-creating-two-tier-access-system 2024-08-22T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nice-rejects-alzheimer-s-drug-lecanemab-despite-mhra-approval-creating-two-tier-access-system 2024-08-22T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/key-leadership-changes-reshape-pharmaceutical-services-landscape-in-july-2024 2024-08-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-leadership-changes-reshape-pharmaceutical-services-landscape-in-july-2024 2024-08-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/federal-circuit-reverses-patent-invalidation-for-allergan-s-ibs-d-drug-viberzi-in-landmark-double-patenting-case 2024-08-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/federal-circuit-reverses-patent-invalidation-for-allergan-s-ibs-d-drug-viberzi-in-landmark-double-patenting-case 2024-08-22T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/molecule-one-pager-kt-474-sar444656 2024-08-21T21:56:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/molecule-one-pager-kt-474-sar444656 2024-08-21T21:56:07+00:00 weekly 0.7 https://trial.medpath.com/news/leclaza-in-combination-with-rybrevant-receives-first-u-s-fda-approval-for-a-korea-born-anticancer-drug 2024-08-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leclaza-in-combination-with-rybrevant-receives-first-u-s-fda-approval-for-a-korea-born-anticancer-drug 2024-08-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-pharmaceuticals-announces-fda-advisory-committee-globenewswire 2024-08-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lexicon-pharmaceuticals-announces-fda-advisory-committee-globenewswire 2024-08-21T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-for-patients-with-egfr-mutated-advanced-lung-cancer 2024-08-20T21:08:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-rybrevant-amivantamab-vmjw-plus-lazcluze-lazertinib-for-patients-with-egfr-mutated-advanced-lung-cancer 2024-08-20T21:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/ftc-orange-book-patent-challenge-initiative-shows-mixed-results-as-most-listings-remain-in-force 2024-08-20T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ftc-orange-book-patent-challenge-initiative-shows-mixed-results-as-most-listings-remain-in-force 2024-08-20T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-reduced-the-risk-of-developing-type-2-diabetes-by-94-in-adults-with-pre-diabetes-and-obesity-or-overweight 2024-08-20T05:08:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tirzepatide-reduced-the-risk-of-developing-type-2-diabetes-by-94-in-adults-with-pre-diabetes-and-obesity-or-overweight 2024-08-20T05:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-provides-update-on-biologics-license-application-for-linvoseltamab 2024-08-20T02:08:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-provides-update-on-biologics-license-application-for-linvoseltamab 2024-08-20T02:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-receives-us-fda-breakthrough-therapy-designation-for-b7-h3-targeted-antibody-drug-conjugate-gsk5764227-in-relapsed-or-refractory-extensive-stage-small-cell-lung-cancer 2024-08-20T02:08:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-receives-us-fda-breakthrough-therapy-designation-for-b7-h3-targeted-antibody-drug-conjugate-gsk5764227-in-relapsed-or-refractory-extensive-stage-small-cell-lung-cancer 2024-08-20T02:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-grants-tentative-approval-of-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulmonary-arterial-hypertension-pah-and-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild 2024-08-19T21:08:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-fda-grants-tentative-approval-of-yutrepia-treprostinil-inhalation-powder-for-patients-with-pulmonary-arterial-hypertension-pah-and-pulmonary-hypertension-associated-with-interstitial-lung-disease-ph-ild 2024-08-19T21:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/moma-therapeutics-initiates-phase-1-trial-for-novel-dna-repair-inhibitor-moma-313 2024-08-19T11:09:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moma-therapeutics-initiates-phase-1-trial-for-novel-dna-repair-inhibitor-moma-313 2024-08-19T11:09:39+00:00 weekly 0.7 https://trial.medpath.com/news/arthrosi-therapeutics-receives-fda-fast-track-designation-for-ar882-in-tophaceous-gout 2024-08-19T02:08:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arthrosi-therapeutics-receives-fda-fast-track-designation-for-ar882-in-tophaceous-gout 2024-08-19T02:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/tafasitamab-regimen-shows-promise-in-improving-pfs-for-advanced-follicular-lymphoma-patients 2024-08-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tafasitamab-regimen-shows-promise-in-improving-pfs-for-advanced-follicular-lymphoma-patients 2024-08-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/who-announces-new-treatment-regimens-for-drug-resistant-tuberculosis 2024-08-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/who-announces-new-treatment-regimens-for-drug-resistant-tuberculosis 2024-08-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-biontech-covid-flu-combo-vaccine-faces-setback-due-to-influenza-b-response 2024-08-18T23:38:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-biontech-covid-flu-combo-vaccine-faces-setback-due-to-influenza-b-response 2024-08-18T23:38:51+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-completed-for-phase-2-clinical-trial-evaluating-vg081821ac-for-the-treatment-of-parkinson-s-disease 2024-08-18T22:08:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enrollment-completed-for-phase-2-clinical-trial-evaluating-vg081821ac-for-the-treatment-of-parkinson-s-disease 2024-08-18T22:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/cilta-cel-for-functional-high-risk-myeloma-healthtree 2024-08-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cilta-cel-for-functional-high-risk-myeloma-healthtree 2024-08-17T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-approved-in-the-us-for-the-treatment-of-resectable-non-small-cell-lung-cancer-before-and-after-surgery 2024-08-16T23:08:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-approved-in-the-us-for-the-treatment-of-resectable-non-small-cell-lung-cancer-before-and-after-surgery 2024-08-16T23:08:36+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-accepts-for-priority-review-decipheras-new-drug-application-for-vimseltinib-for-the-treatment-of-patients-with-tenosynovial-giant-cell-tumor-tgct 2024-08-16T23:08:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-food-and-drug-administration-accepts-for-priority-review-decipheras-new-drug-application-for-vimseltinib-for-the-treatment-of-patients-with-tenosynovial-giant-cell-tumor-tgct 2024-08-16T23:08:14+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-and-biontech-provide-update-on-mrna-based-combination-vaccine-program-against-influenza-and-covid-19-in-individuals-18-64-years-of-age 2024-08-16T02:08:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-and-biontech-provide-update-on-mrna-based-combination-vaccine-program-against-influenza-and-covid-19-in-individuals-18-64-years-of-age 2024-08-16T02:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/expanding-treatment-options-for-her2-breast-cancer-patients 2024-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expanding-treatment-options-for-her2-breast-cancer-patients 2024-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/citius-oncology-launches-following-fda-approval-of-lymphir 2024-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citius-oncology-launches-following-fda-approval-of-lymphir 2024-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ptab-invalidates-multiple-regeneron-eylea-patents-as-biosimilar-competition-intensifies 2024-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ptab-invalidates-multiple-regeneron-eylea-patents-as-biosimilar-competition-intensifies 2024-08-16T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/vericel-announces-fda-approval-of-nexobrid-for-the-treatment-of-pediatric-patients-with-severe-thermal-burns 2024-08-15T20:08:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vericel-announces-fda-approval-of-nexobrid-for-the-treatment-of-pediatric-patients-with-severe-thermal-burns 2024-08-15T20:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-s-genzyme-sues-sarepta-over-elevidys-gene-therapy-patent-infringement 2024-08-15T16:56:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-s-genzyme-sues-sarepta-over-elevidys-gene-therapy-patent-infringement 2024-08-15T16:56:07+00:00 weekly 0.7 https://trial.medpath.com/news/cresilon-receives-fda-clearance-for-traumagel 2024-08-15T13:32:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cresilon-receives-fda-clearance-for-traumagel 2024-08-15T13:32:49+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-drug-price-negotiations-deliver-6-billion-in-savings-with-22-79-discounts-on-10-blockbuster-medications 2024-08-15T08:35:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicare-drug-price-negotiations-deliver-6-billion-in-savings-with-22-79-discounts-on-10-blockbuster-medications 2024-08-15T08:35:46+00:00 weekly 0.7 https://trial.medpath.com/news/tecovirimat-is-safe-but-did-not-improve-clade-i-mpox-resolution-in-democratic-republic-of-the-congo 2024-08-15T02:08:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tecovirimat-is-safe-but-did-not-improve-clade-i-mpox-resolution-in-democratic-republic-of-the-congo 2024-08-15T02:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/prota-therapeutics-announces-publication-in-allergy-of-long-term-peanut-allergy-study-confirming-clinical-remission-as-the-optimal-treatment-outcome 2024-08-15T00:08:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/prota-therapeutics-announces-publication-in-allergy-of-long-term-peanut-allergy-study-confirming-clinical-remission-as-the-optimal-treatment-outcome 2024-08-15T00:08:44+00:00 weekly 0.7 https://trial.medpath.com/news/tempest-announces-successful-end-of-phase-2-meeting-with-fda-for-amezalpat-tpst-1120-to-treat-first-line-hepatocellular-carcinoma 2024-08-15T00:08:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tempest-announces-successful-end-of-phase-2-meeting-with-fda-for-amezalpat-tpst-1120-to-treat-first-line-hepatocellular-carcinoma 2024-08-15T00:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-granted-priority-review-and-breakthrough-therapy 2024-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-granted-priority-review-and-breakthrough-therapy 2024-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-and-rare-pediatric-disease-designations-to-atsn-201-for-x-linked-retinoschisis 2024-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-and-rare-pediatric-disease-designations-to-atsn-201-for-x-linked-retinoschisis 2024-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-randomized-double-blind-placebo-controlled-phase-3 2024-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-randomized-double-blind-placebo-controlled-phase-3 2024-08-15T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-niktimvo-axatilimab-csfr-for-the-treatment-of-chronic-graft-versus-host-disease-gvhd 2024-08-14T22:08:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-niktimvo-axatilimab-csfr-for-the-treatment-of-chronic-graft-versus-host-disease-gvhd 2024-08-14T22:08:53+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-accelerated-approval-for-livdelzi-seladelpar-for-the-treatment-of-primary-biliary-cholangitis 2024-08-14T22:08:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-accelerated-approval-for-livdelzi-seladelpar-for-the-treatment-of-primary-biliary-cholangitis 2024-08-14T22:08:15+00:00 weekly 0.7 https://trial.medpath.com/news/precigen-announces-second-quarter-and-first-half-2024-financial-results-and-business-updates 2024-08-14T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/precigen-announces-second-quarter-and-first-half-2024-financial-results-and-business-updates 2024-08-14T16:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/evolution-of-pnh-treatment-new-therapies-transform-management-of-rare-blood-disorder 2024-08-14T11:24:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evolution-of-pnh-treatment-new-therapies-transform-management-of-rare-blood-disorder 2024-08-14T11:24:32+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-launches-personalised-cancer-vaccine-program-across-england-with-thousands-expected-to-enroll 2024-08-14T06:50:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-launches-personalised-cancer-vaccine-program-across-england-with-thousands-expected-to-enroll 2024-08-14T06:50:07+00:00 weekly 0.7 https://trial.medpath.com/news/ai-and-multi-omics-drive-breakthrough-advances-in-anti-aging-drug-development 2024-08-14T05:25:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-and-multi-omics-drive-breakthrough-advances-in-anti-aging-drug-development 2024-08-14T05:25:28+00:00 weekly 0.7 https://trial.medpath.com/news/first-clinical-trial-of-paradoxical-intervention-for-cancer-to-begin-soon 2024-08-14T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-clinical-trial-of-paradoxical-intervention-for-cancer-to-begin-soon 2024-08-14T05:00:08+00:00 weekly 0.7 https://trial.medpath.com/news/accutar-biotechnology-receives-fda-fast-track-designation-for-ac699-in-er-her2-breast-cancer 2024-08-14T01:08:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accutar-biotechnology-receives-fda-fast-track-designation-for-ac699-in-er-her2-breast-cancer 2024-08-14T01:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/candidate-malaria-vaccine-provides-lasting-protection-in-nih-sponsored-trials 2024-08-14T01:08:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/candidate-malaria-vaccine-provides-lasting-protection-in-nih-sponsored-trials 2024-08-14T01:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-submits-completed-ugn-102-nda-seeking-approval-as-the-first-fda-approved-treatment-for-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer 2024-08-14T01:08:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/urogen-submits-completed-ugn-102-nda-seeking-approval-as-the-first-fda-approved-treatment-for-low-grade-intermediate-risk-non-muscle-invasive-bladder-cancer 2024-08-14T01:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/moleculin-advances-aml-treatment-with-positive-fda-feedback-and-plans-for-phase-3-miracle-trial 2024-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/moleculin-advances-aml-treatment-with-positive-fda-feedback-and-plans-for-phase-3-miracle-trial 2024-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-positive-phase-3-data-for-izokibep-biospace 2024-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-inc-announces-positive-phase-3-data-for-izokibep-biospace 2024-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-stock-rating-downgraded-amid-pipeline-shift 2024-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-stock-rating-downgraded-amid-pipeline-shift 2024-08-14T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/enrollment-completed-for-the-sad-part-1-of-phase-1-clinical-trial-evaluating-da-1726-for-the-treatment-of-obesity 2024-08-13T23:08:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enrollment-completed-for-the-sad-part-1-of-phase-1-clinical-trial-evaluating-da-1726-for-the-treatment-of-obesity 2024-08-13T23:08:31+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nemluvio-nemolizumab-for-the-treatment-of-adult-patients-with-prurigo-nodularis 2024-08-13T21:08:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-nemluvio-nemolizumab-for-the-treatment-of-adult-patients-with-prurigo-nodularis 2024-08-13T21:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/heparegenix-lands-eur15m-to-advance-liver-regeneration-drug-into-clinical 2024-08-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/heparegenix-lands-eur15m-to-advance-liver-regeneration-drug-into-clinical 2024-08-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-announces-layoffs-strategy-shift-after-late-stage-trial-results-for-anti-inflammatory-drug 2024-08-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-announces-layoffs-strategy-shift-after-late-stage-trial-results-for-anti-inflammatory-drug 2024-08-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-platforms-transform-precision-medicine-development-through-advanced-data-analytics 2024-08-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/real-world-evidence-platforms-transform-precision-medicine-development-through-advanced-data-analytics 2024-08-13T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/federal-court-denies-novartis-injunction-against-entresto-generic-clearing-path-for-msn-launch 2024-08-12T22:53:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/federal-court-denies-novartis-injunction-against-entresto-generic-clearing-path-for-msn-launch 2024-08-12T22:53:32+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-clinical-hold-on-4d-molecular-therapeutics-fabry-disease-gene-therapy-trial 2024-08-12T15:00:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-lifts-clinical-hold-on-4d-molecular-therapeutics-fabry-disease-gene-therapy-trial 2024-08-12T15:00:11+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-therapeutics-reports-progress-in-q2-2024-earnings-call 2024-08-12T14:12:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kymera-therapeutics-reports-progress-in-q2-2024-earnings-call 2024-08-12T14:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/amylyx-s-amx0035-shows-promise-in-alzheimer-s-disease-biomarker-study 2024-08-12T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amylyx-s-amx0035-shows-promise-in-alzheimer-s-disease-biomarker-study 2024-08-12T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacosmos-group-acquires-g1-therapeutics-for-405-million-to-expand-cosela-access-for-cancer-patients 2024-08-12T09:26:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacosmos-group-acquires-g1-therapeutics-for-405-million-to-expand-cosela-access-for-cancer-patients 2024-08-12T09:26:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-enzeevu-aflibercept-abzv-a-biosimilar-to-eylea 2024-08-12T06:08:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-enzeevu-aflibercept-abzv-a-biosimilar-to-eylea 2024-08-12T06:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/scpharmaceuticals-announces-fda-approval-of-supplemental-new-drug-application-expanding-the-furoscix-indication-in-heart-failure 2024-08-12T01:08:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scpharmaceuticals-announces-fda-approval-of-supplemental-new-drug-application-expanding-the-furoscix-indication-in-heart-failure 2024-08-12T01:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/lenz-therapeutics-announces-submission-of-new-drug-application-to-u-s-food-and-drug-administration-for-lnz100-for-the-treatment-of-presbyopia 2024-08-12T01:08:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenz-therapeutics-announces-submission-of-new-drug-application-to-u-s-food-and-drug-administration-for-lnz100-for-the-treatment-of-presbyopia 2024-08-12T01:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/viva-biotech-s-portfolio-companies-make-significant-strides-in-biopharmaceutical-innovation 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/viva-biotech-s-portfolio-companies-make-significant-strides-in-biopharmaceutical-innovation 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iaso-bio-secures-fda-approval-for-bcma-car-t-therapy-in-multiple-autoimmune-diseases 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iaso-bio-secures-fda-approval-for-bcma-car-t-therapy-in-multiple-autoimmune-diseases 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/key-developments-in-biosimilars-and-pharmaceuticals-in-2024 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/key-developments-in-biosimilars-and-pharmaceuticals-in-2024 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/brazil-cancer-drugs-market-clinical-trials-report-2024-brazil-emerges-as-a-leading-force-in-cancer-drug-clinical-trials 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brazil-cancer-drugs-market-clinical-trials-report-2024-brazil-emerges-as-a-leading-force-in-cancer-drug-clinical-trials 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-sglt2-inhibitors-improve-renal-function-in-non-diabetic-ckd-patients 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shows-sglt2-inhibitors-improve-renal-function-in-non-diabetic-ckd-patients 2024-08-12T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/neurotech-provides-update-on-bla-for-nt-501-as-a 2024-08-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neurotech-provides-update-on-bla-for-nt-501-as-a 2024-08-11T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sanofis-sarclisa-wins-in-transplant-eligible-multiple-myeloma-trial 2024-08-10T17:11:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofis-sarclisa-wins-in-transplant-eligible-multiple-myeloma-trial 2024-08-10T17:11:25+00:00 weekly 0.7 https://trial.medpath.com/news/lykos-therapeutics-announces-complete-response-letter-for-midomafetamine-capsules-for-ptsd 2024-08-09T21:08:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lykos-therapeutics-announces-complete-response-letter-for-midomafetamine-capsules-for-ptsd 2024-08-09T21:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/first-patients-enrolled-in-us-pivotal-study-of-ai-based-image-analysis-module-for-lung-cancer 2024-08-09T21:08:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-patients-enrolled-in-us-pivotal-study-of-ai-based-image-analysis-module-for-lung-cancer 2024-08-09T21:08:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-neffy-epinephrine-nasal-spray-needle-free-treatment-for-type-i-allergic-reactions-including-anaphylaxis 2024-08-09T07:08:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-neffy-epinephrine-nasal-spray-needle-free-treatment-for-type-i-allergic-reactions-including-anaphylaxis 2024-08-09T07:08:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd-calling-for-additional-study 2024-08-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-rejects-psychedelic-mdma-as-treatment-for-ptsd-calling-for-additional-study 2024-08-09T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lymphir-denileukin-diftitox-cxdl-immunotherapy-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma 2024-08-08T22:08:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lymphir-denileukin-diftitox-cxdl-immunotherapy-for-the-treatment-of-adults-with-relapsed-or-refractory-cutaneous-t-cell-lymphoma 2024-08-08T22:08:26+00:00 weekly 0.7 https://trial.medpath.com/news/westgene-to-advance-clinical-trials-following-dual-ind-approvals-for-world-s-first-eb-virus-related-mrna-therapeutic-cancer-vaccine 2024-08-08T22:08:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/westgene-to-advance-clinical-trials-following-dual-ind-approvals-for-world-s-first-eb-virus-related-mrna-therapeutic-cancer-vaccine 2024-08-08T22:08:00+00:00 weekly 0.7 https://trial.medpath.com/news/kymera-therapeutics-shares-price-target-rises-on-positive-development 2024-08-08T11:28:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kymera-therapeutics-shares-price-target-rises-on-positive-development 2024-08-08T11:28:08+00:00 weekly 0.7 https://trial.medpath.com/news/nanoviricides-provides-an-update-on-its-clinical-program 2024-08-08T11:14:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nanoviricides-provides-an-update-on-its-clinical-program 2024-08-08T11:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/blarcamesine-shows-significant-slowing-of-alzheimer-disease-in-phase-2-3-trial 2024-08-08T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/blarcamesine-shows-significant-slowing-of-alzheimer-disease-in-phase-2-3-trial 2024-08-08T10:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/policy-change-alone-wont-achieve-equity-in-clinical-trial-participation 2024-08-08T09:00:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/policy-change-alone-wont-achieve-equity-in-clinical-trial-participation 2024-08-08T09:00:09+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-receives-fda-accelerated-approval-for-fabhalta-iptacopan-for-the-reduction-of-proteinuria-in-primary-iga-nephropathy-igan 2024-08-08T06:08:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-receives-fda-accelerated-approval-for-fabhalta-iptacopan-for-the-reduction-of-proteinuria-in-primary-iga-nephropathy-igan 2024-08-08T06:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-dry-eye-disease-clinical-trial-of-reproxalap 2024-08-08T06:08:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aldeyra-therapeutics-achieves-primary-endpoint-in-phase-3-dry-eye-disease-clinical-trial-of-reproxalap 2024-08-08T06:08:04+00:00 weekly 0.7 https://trial.medpath.com/news/merck-provides-update-on-phase-3-keyvibe-008-trial-evaluating-an-investigational-fixed-dose-combination-of-vibostolimab-and-pembrolizumab-in-patients-with-extensive-stage-small-cell-lung-cancer 2024-08-08T06:08:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-provides-update-on-phase-3-keyvibe-008-trial-evaluating-an-investigational-fixed-dose-combination-of-vibostolimab-and-pembrolizumab-in-patients-with-extensive-stage-small-cell-lung-cancer 2024-08-08T06:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/stoke-therapeutics-eyes-phase-iii-dravet-syndrome-trial-as-fda 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stoke-therapeutics-eyes-phase-iii-dravet-syndrome-trial-as-fda 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fractyl-health-announces-clinical-results-from-german-real-world-registry 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fractyl-health-announces-clinical-results-from-german-real-world-registry 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/upstream-bio-announces-200m-series-b-financing-to-advance-upb-101-for 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/upstream-bio-announces-200m-series-b-financing-to-advance-upb-101-for 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/verona-pharma-reports-second-quarter-2024-financial-results-and 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/verona-pharma-reports-second-quarter-2024-financial-results-and 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kura-oncology-announces-fda-clearance-of-ind-application-for-menin-inhibitor-ziftomenib-in-advanced-gastrointestinal-stromal-tumors-gist 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kura-oncology-announces-fda-clearance-of-ind-application-for-menin-inhibitor-ziftomenib-in-advanced-gastrointestinal-stromal-tumors-gist 2024-08-08T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nhs-england-approves-first-crispr-gene-editing-therapy-for-beta-thalassaemia-treatment 2024-08-07T23:17:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nhs-england-approves-first-crispr-gene-editing-therapy-for-beta-thalassaemia-treatment 2024-08-07T23:17:32+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zurnai-nalmefene-hydrochloride-auto-injector-for-the-emergency-treatment-of-known-or-suspected-opioid-overdose 2024-08-07T21:08:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zurnai-nalmefene-hydrochloride-auto-injector-for-the-emergency-treatment-of-known-or-suspected-opioid-overdose 2024-08-07T21:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-crexont-carbidopa-and-levodopa-extended-release-capsules-for-the-treatment-of-parkinsons-disease 2024-08-07T08:08:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-crexont-carbidopa-and-levodopa-extended-release-capsules-for-the-treatment-of-parkinsons-disease 2024-08-07T08:08:01+00:00 weekly 0.7 https://trial.medpath.com/news/groundbreaking-nipocalimab-study-of-pregnant-individuals-at-high-risk-for-early-onset-severe-hemolytic-disease-of-the-fetus-and-newborn-published-in-the-new-england-journal-of-medicine 2024-08-07T05:08:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/groundbreaking-nipocalimab-study-of-pregnant-individuals-at-high-risk-for-early-onset-severe-hemolytic-disease-of-the-fetus-and-newborn-published-in-the-new-england-journal-of-medicine 2024-08-07T05:08:13+00:00 weekly 0.7 https://trial.medpath.com/news/nice-approves-eladynos-for-postmenopausal-osteoporosis-but-nhs-diagnostic-gaps-pose-access-challenges 2024-08-07T01:46:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nice-approves-eladynos-for-postmenopausal-osteoporosis-but-nhs-diagnostic-gaps-pose-access-challenges 2024-08-07T01:46:35+00:00 weekly 0.7 https://trial.medpath.com/news/4sc-announces-half-year-report-2024-and-provides-update 2024-08-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4sc-announces-half-year-report-2024-and-provides-update 2024-08-07T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/olema-oncology-reports-second-quarter-2024-financial-results-and-corporate-update 2024-08-06T21:50:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/olema-oncology-reports-second-quarter-2024-financial-results-and-corporate-update 2024-08-06T21:50:00+00:00 weekly 0.7 https://trial.medpath.com/news/julys-molecules-on-the-move 2024-08-06T21:48:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/julys-molecules-on-the-move 2024-08-06T21:48:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-voranigo-vorasidenib-for-the-treatment-of-grade-2-idh-mutant-glioma 2024-08-06T19:08:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-voranigo-vorasidenib-for-the-treatment-of-grade-2-idh-mutant-glioma 2024-08-06T19:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/xdemvy-the-first-fda-approved-treatment-for-demodex-blepharitis 2024-08-06T16:34:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xdemvy-the-first-fda-approved-treatment-for-demodex-blepharitis 2024-08-06T16:34:31+00:00 weekly 0.7 https://trial.medpath.com/news/eo-3021-shows-promise-in-treating-advanced-solid-tumors-expressing-cldn18-2 2024-08-06T16:12:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eo-3021-shows-promise-in-treating-advanced-solid-tumors-expressing-cldn18-2 2024-08-06T16:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/dr-gerds-on-unmet-needs-in-low-risk-myelofibrosis 2024-08-06T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-gerds-on-unmet-needs-in-low-risk-myelofibrosis 2024-08-06T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/safe-and-intriguing-natures-drugs-taking-on-complex-diseases 2024-08-06T09:00:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/safe-and-intriguing-natures-drugs-taking-on-complex-diseases 2024-08-06T09:00:07+00:00 weekly 0.7 https://trial.medpath.com/news/daiichi-sankyo-and-merck-expand-collaboration-to-develop-novel-dll3-targeting-t-cell-engager-for-small-cell-lung-cancer 2024-08-06T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/daiichi-sankyo-and-merck-expand-collaboration-to-develop-novel-dll3-targeting-t-cell-engager-for-small-cell-lung-cancer 2024-08-06T06:45:00+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-kerendia-and-nubeqa-drive-strong-pharmaceutical-growth-q2-sales-hit-eur11-1-billion 2024-08-06T03:20:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-s-kerendia-and-nubeqa-drive-strong-pharmaceutical-growth-q2-sales-hit-eur11-1-billion 2024-08-06T03:20:58+00:00 weekly 0.7 https://trial.medpath.com/news/george-medicines-announces-gmrx2-nda-filing-to-fda 2024-08-06T02:08:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/george-medicines-announces-gmrx2-nda-filing-to-fda 2024-08-06T02:08:34+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1-receptor-agonists-show-survival-benefit-in-cancer-patients-with-type-2-diabetes 2024-08-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1-receptor-agonists-show-survival-benefit-in-cancer-patients-with-type-2-diabetes 2024-08-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/abivax-s-abtect-phase-3-trial-reaches-key-enrollment-milestone 2024-08-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abivax-s-abtect-phase-3-trial-reaches-key-enrollment-milestone 2024-08-06T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/shanton-pharma-completes-enrollment-for-phase-2b-trial-of-sap-001-in-refractory-gout 2024-08-05T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shanton-pharma-completes-enrollment-for-phase-2b-trial-of-sap-001-in-refractory-gout 2024-08-05T13:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/turn-therapeutics-topical-atopic-dermatitis-candidate-significantly-inhibits-key-cytokines-in-expansion-study-of-flagship-formula 2024-08-05T11:08:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/turn-therapeutics-topical-atopic-dermatitis-candidate-significantly-inhibits-key-cytokines-in-expansion-study-of-flagship-formula 2024-08-05T11:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/novel-nanoparticle-immunotherapy-shows-promise-in-delaying-prostate-cancer-treatment-resistance 2024-08-05T09:41:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-nanoparticle-immunotherapy-shows-promise-in-delaying-prostate-cancer-treatment-resistance 2024-08-05T09:41:00+00:00 weekly 0.7 https://trial.medpath.com/news/jak-inhibitors-boost-immunotherapy-response-rates-in-lung-cancer-and-lymphoma-trials 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jak-inhibitors-boost-immunotherapy-response-rates-in-lung-cancer-and-lymphoma-trials 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/enzene-biosciences-establishes-50-million-new-jersey-manufacturing-facility-with-continuous-biologics-platform 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enzene-biosciences-establishes-50-million-new-jersey-manufacturing-facility-with-continuous-biologics-platform 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/car-e-platform-shows-promise-in-preventing-car-t-cell-therapy-relapse 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/car-e-platform-shows-promise-in-preventing-car-t-cell-therapy-relapse 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/3d-printing-revolutionizes-microneedle-manufacturing-for-enhanced-transdermal-drug-delivery 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/3d-printing-revolutionizes-microneedle-manufacturing-for-enhanced-transdermal-drug-delivery 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ocugen-inc-announces-fda-approval-of-expanded-access-program-for-patients-with-retinitis-pigmentosa 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocugen-inc-announces-fda-approval-of-expanded-access-program-for-patients-with-retinitis-pigmentosa 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/cell-and-gene-therapy-shows-early-promise-against 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cell-and-gene-therapy-shows-early-promise-against 2024-08-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-and-sanegenebio-announce-first-participant-dosed-in-a-phase-1-clinical-trial-of-ibi3016 2024-08-04T02:08:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovent-and-sanegenebio-announce-first-participant-dosed-in-a-phase-1-clinical-trial-of-ibi3016 2024-08-04T02:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advisory-committee-votes-favorably-that-the-data-support-arimoclomol-as-effective-treatment-for-patients-with-niemann-pick-disease-type-c 2024-08-02T21:08:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-advisory-committee-votes-favorably-that-the-data-support-arimoclomol-as-effective-treatment-for-patients-with-niemann-pick-disease-type-c 2024-08-02T21:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-awards-orphan-drug-designation-to-avutometinib-plus-defactinib-for-pancreatic-cancer-treatment 2024-08-02T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-awards-orphan-drug-designation-to-avutometinib-plus-defactinib-for-pancreatic-cancer-treatment 2024-08-02T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-s-weight-loss-drug-tirzepatide-approved-in-china 2024-08-02T08:00:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-s-weight-loss-drug-tirzepatide-approved-in-china 2024-08-02T08:00:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-july-2024-roundup-breakthroughs-and-milestones 2024-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-july-2024-roundup-breakthroughs-and-milestones 2024-08-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-pioneer-jim-wilson-departs-upenn-to-launch-two-new-companies 2024-08-01T13:18:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-pioneer-jim-wilson-departs-upenn-to-launch-two-new-companies 2024-08-01T13:18:19+00:00 weekly 0.7 https://trial.medpath.com/news/ideate-lung02-phase-3-trial-of-ifinatamab-deruxtecan-initiated-in-patients-with-relapsed-small-cell-lung-cancer 2024-08-01T06:08:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ideate-lung02-phase-3-trial-of-ifinatamab-deruxtecan-initiated-in-patients-with-relapsed-small-cell-lung-cancer 2024-08-01T06:08:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-jemperli-dostarlimab-gxly-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer 2024-08-01T04:08:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-jemperli-dostarlimab-gxly-plus-chemotherapy-approval-to-all-adult-patients-with-primary-advanced-or-recurrent-endometrial-cancer 2024-08-01T04:08:09+00:00 weekly 0.7 https://trial.medpath.com/news/dose-dense-chemotherapy-preferred-for-node-positive-breast-cancer-patients-regardless-of-bmi 2024-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dose-dense-chemotherapy-preferred-for-node-positive-breast-cancer-patients-regardless-of-bmi 2024-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/resmetirom-and-glp-1-agonists-show-promise-in-treating-mash 2024-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/resmetirom-and-glp-1-agonists-show-promise-in-treating-mash 2024-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-therapy-in-high-grade-serous-ovarian-cancer 2024-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeted-therapy-in-high-grade-serous-ovarian-cancer 2024-08-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-startup-airna-raises-60m-for-rna-editing-medicines 2024-07-31T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotech-startup-airna-raises-60m-for-rna-editing-medicines 2024-07-31T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/citryll-completes-phase-i-dosing-for-novel-anti-inflammatory-drug-cit-013-targeting-neutrophil-extracellular-traps 2024-07-31T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/citryll-completes-phase-i-dosing-for-novel-anti-inflammatory-drug-cit-013-targeting-neutrophil-extracellular-traps 2024-07-31T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fibrogen-terminates-pamrevlumab-development-after-failed-pancreatic-cancer-trials-announces-major-workforce-reduction 2024-07-31T02:58:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fibrogen-terminates-pamrevlumab-development-after-failed-pancreatic-cancer-trials-announces-major-workforce-reduction 2024-07-31T02:58:57+00:00 weekly 0.7 https://trial.medpath.com/news/hispanic-patients-with-alcohol-use-disorder-at-higher-risk-for-liver-diseases 2024-07-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hispanic-patients-with-alcohol-use-disorder-at-higher-risk-for-liver-diseases 2024-07-31T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/biontech-announces-positive-topline-phase-2-results-for-mrna-immunotherapy-candidate-bnt111-in-patients-with-advanced-melanoma 2024-07-30T21:08:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biontech-announces-positive-topline-phase-2-results-for-mrna-immunotherapy-candidate-bnt111-in-patients-with-advanced-melanoma 2024-07-30T21:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/fractyl-health-s-revita-system-receives-fda-breakthrough-device-designation 2024-07-30T11:27:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fractyl-health-s-revita-system-receives-fda-breakthrough-device-designation 2024-07-30T11:27:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-compugen-s-phase-i-trial-for-solid-tumour-treatment 2024-07-30T10:51:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-compugen-s-phase-i-trial-for-solid-tumour-treatment 2024-07-30T10:51:51+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-discontinues-duchenne-gene-therapy-development-following-phase-3-trial-failure 2024-07-30T10:18:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-discontinues-duchenne-gene-therapy-development-following-phase-3-trial-failure 2024-07-30T10:18:00+00:00 weekly 0.7 https://trial.medpath.com/news/psoriasis-drug-ustekinumab-shows-promise-in-preserving-insulin-production-in-young-type-1-diabetes-patients 2024-07-30T09:18:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/psoriasis-drug-ustekinumab-shows-promise-in-preserving-insulin-production-in-young-type-1-diabetes-patients 2024-07-30T09:18:14+00:00 weekly 0.7 https://trial.medpath.com/news/high-court-rules-on-moderna-pfizer-biontech-covid-19-vaccine-patent-dispute-setting-precedent-for-mrna-technology-rights 2024-07-30T08:27:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-court-rules-on-moderna-pfizer-biontech-covid-19-vaccine-patent-dispute-setting-precedent-for-mrna-technology-rights 2024-07-30T08:27:00+00:00 weekly 0.7 https://trial.medpath.com/news/vertex-announces-fda-acceptance-of-new-drug-application-for-suzetrigine-for-the-treatment-of-moderate-to-severe-acute-pain 2024-07-30T02:07:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vertex-announces-fda-acceptance-of-new-drug-application-for-suzetrigine-for-the-treatment-of-moderate-to-severe-acute-pain 2024-07-30T02:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-regimen-approved-in-the-u-s-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible 2024-07-30T02:07:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/darzalex-faspro-daratumumab-and-hyaluronidase-fihj-based-quadruplet-regimen-approved-in-the-u-s-for-patients-with-newly-diagnosed-multiple-myeloma-who-are-transplant-eligible 2024-07-30T02:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/fda-expands-blinatumomab-approval-in-early-stage 2024-07-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-expands-blinatumomab-approval-in-early-stage 2024-07-30T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/syndax-announces-pdufa-action-date-extension-for-revumenib-nda-for-relapsed-or-refractory-kmt2ar-acute-leukemia 2024-07-29T21:07:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syndax-announces-pdufa-action-date-extension-for-revumenib-nda-for-relapsed-or-refractory-kmt2ar-acute-leukemia 2024-07-29T21:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-zunveyl-benzgalantamine-for-the-treatment-of-alzheimer-s-disease 2024-07-29T20:07:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-zunveyl-benzgalantamine-for-the-treatment-of-alzheimer-s-disease 2024-07-29T20:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/nt-0796 2024-07-29T14:38:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nt-0796 2024-07-29T14:38:52+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-and-flagship-pioneering-launch-7-billion-strategic-alliance-for-novel-therapeutics-development 2024-07-29T12:44:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-and-flagship-pioneering-launch-7-billion-strategic-alliance-for-novel-therapeutics-development 2024-07-29T12:44:30+00:00 weekly 0.7 https://trial.medpath.com/news/promis-reports-positive-phase-ia-trial-results-for-alzheimer-s-treatment 2024-07-29T08:36:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promis-reports-positive-phase-ia-trial-results-for-alzheimer-s-treatment 2024-07-29T08:36:48+00:00 weekly 0.7 https://trial.medpath.com/news/grifols-receives-approval-for-expanded-xembify-immune-globulin-subcutaneous-human-klhw-label-in-u-s 2024-07-29T05:07:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/grifols-receives-approval-for-expanded-xembify-immune-globulin-subcutaneous-human-klhw-label-in-u-s 2024-07-29T05:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-efficacy-safety-and-tolerability-of-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia 2024-07-29T02:08:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/topline-data-from-pivotal-phase-3-brooklyn-clinical-trial-evaluating-efficacy-safety-and-tolerability-of-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia 2024-07-29T02:08:32+00:00 weekly 0.7 https://trial.medpath.com/news/volunteers-needed-for-the-dog-aging-project 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/volunteers-needed-for-the-dog-aging-project 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lomecel-b-meets-key-objectives-in-phase-iia-alzheimer-s 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lomecel-b-meets-key-objectives-in-phase-iia-alzheimer-s 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-scemblix-r-granted-fda-priority-review-for-the 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-scemblix-r-granted-fda-priority-review-for-the 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-blood-based-cancer-test-in-medical-breakthrough 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-blood-based-cancer-test-in-medical-breakthrough 2024-07-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fnih-study-validates-blood-tests-for-alzheimer-s-detection-potentially-replacing-invasive-spinal-taps 2024-07-28T11:53:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fnih-study-validates-blood-tests-for-alzheimer-s-detection-potentially-replacing-invasive-spinal-taps 2024-07-28T11:53:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-erzofri-paliperidone-palmitate-for-the-treatment-of-schizophrenia-and-schizoaffective-disorder 2024-07-28T01:07:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-erzofri-paliperidone-palmitate-for-the-treatment-of-schizophrenia-and-schizoaffective-disorder 2024-07-28T01:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/alector-presents-baseline-characteristics-for-invoke-2-phase-2-clinical-trial-of-al002-at-the-alzheimer-s-association-international-conference-r-2024-aaic-r 2024-07-28T01:07:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alector-presents-baseline-characteristics-for-invoke-2-phase-2-clinical-trial-of-al002-at-the-alzheimer-s-association-international-conference-r-2024-aaic-r 2024-07-28T01:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-palforzia-peanut-arachis-hypogaea-allergen-powder-dnfp-for-use-in-individuals-ages-1-through-3-years-with-a-confirmed-diagnosis-of-peanut-allergy 2024-07-26T23:07:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-palforzia-peanut-arachis-hypogaea-allergen-powder-dnfp-for-use-in-individuals-ages-1-through-3-years-with-a-confirmed-diagnosis-of-peanut-allergy 2024-07-26T23:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-leqselvi-deuruxolitinib-an-oral-jak-inhibitor-for-the-treatment-of-severe-alopecia-areata 2024-07-26T21:07:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-leqselvi-deuruxolitinib-an-oral-jak-inhibitor-for-the-treatment-of-severe-alopecia-areata 2024-07-26T21:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/xspray-pharma-shares-new-information-on-dasynoc-a-novel-cml-treatment-in-development 2024-07-26T20:07:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xspray-pharma-shares-new-information-on-dasynoc-a-novel-cml-treatment-in-development 2024-07-26T20:07:16+00:00 weekly 0.7 https://trial.medpath.com/news/cbm588-may-improve-clinical-outcomes-in-metastatic-rcc 2024-07-26T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cbm588-may-improve-clinical-outcomes-in-metastatic-rcc 2024-07-26T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nicox-completes-u-s-recruitment-for-phase-3-glaucoma-trial-of-ncx-470 2024-07-26T10:12:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nicox-completes-u-s-recruitment-for-phase-3-glaucoma-trial-of-ncx-470 2024-07-26T10:12:01+00:00 weekly 0.7 https://trial.medpath.com/news/third-arc-secures-165m-series-a-to-advance-novel-t-cell-engager-platform-for-cancer-and-inflammation 2024-07-26T03:12:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/third-arc-secures-165m-series-a-to-advance-novel-t-cell-engager-platform-for-cancer-and-inflammation 2024-07-26T03:12:05+00:00 weekly 0.7 https://trial.medpath.com/news/nih-researchers-discover-potential-therapeutic-target-for-degenerative-eye-disease 2024-07-26T03:07:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-researchers-discover-potential-therapeutic-target-for-degenerative-eye-disease 2024-07-26T03:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/guardant-health-invests-in-obviohealth-to-accelerate-digital-oncology-clinical-trials 2024-07-26T02:47:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/guardant-health-invests-in-obviohealth-to-accelerate-digital-oncology-clinical-trials 2024-07-26T02:47:34+00:00 weekly 0.7 https://trial.medpath.com/news/presage-biosciences-announces-first-patient-dosing-of-pure-biologics-ror1-targeting-antibody-for-treatment-of-cancer 2024-07-26T02:07:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/presage-biosciences-announces-first-patient-dosing-of-pure-biologics-ror1-targeting-antibody-for-treatment-of-cancer 2024-07-26T02:07:31+00:00 weekly 0.7 https://trial.medpath.com/news/five-key-strategies-to-revolutionize-clinical-trial-patient-recruitment-in-biopharma 2024-07-26T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/five-key-strategies-to-revolutionize-clinical-trial-patient-recruitment-in-biopharma 2024-07-26T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-completes-first-patient-dosage-of-p53-y220c-activator-in-clinical-trial 2024-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/jacobio-completes-first-patient-dosage-of-p53-y220c-activator-in-clinical-trial 2024-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/ema-approves-second-covid-19-vaccine-as-moderna-receives-conditional-marketing-authorization-in-eu 2024-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-approves-second-covid-19-vaccine-as-moderna-receives-conditional-marketing-authorization-in-eu 2024-07-26T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/walgreens-receives-project-award-oracle-announces-new-ai-capabilities-for-trials-n-power-merck-collaborate-on-oncology-clinical-research-more 2024-07-25T09:00:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/walgreens-receives-project-award-oracle-announces-new-ai-capabilities-for-trials-n-power-merck-collaborate-on-oncology-clinical-research-more 2024-07-25T09:00:01+00:00 weekly 0.7 https://trial.medpath.com/news/mirums-livmarli-now-approved-for-pfic-in-patients-12-months-and-older 2024-07-25T01:07:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mirums-livmarli-now-approved-for-pfic-in-patients-12-months-and-older 2024-07-25T01:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/evidence-meta-analysis-evaluating-minimal-residual-disease-as-an 2024-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evidence-meta-analysis-evaluating-minimal-residual-disease-as-an 2024-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-announces-clinical-supply-agreement-with 2024-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/briacell-announces-clinical-supply-agreement-with 2024-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/windtree-therapeutics-provides-update-on-istaroxime-clinical-development-and-upcoming-clinical-trial-data 2024-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/windtree-therapeutics-provides-update-on-istaroxime-clinical-development-and-upcoming-clinical-trial-data 2024-07-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-a-phase-2-study-of-tpn-101-for-the-treatment-of-c9orf72-related-amyotrophic-lateral-sclerosis-and-or-frontotemporal-dementia 2024-07-24T21:07:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-results-from-a-phase-2-study-of-tpn-101-for-the-treatment-of-c9orf72-related-amyotrophic-lateral-sclerosis-and-or-frontotemporal-dementia 2024-07-24T21:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/sage-therapeutics-and-biogen-announce-topline-results-from-phase-2-kinetic-2-study-of-sage-324-biib124-for-the-treatment-of-essential-tremor 2024-07-24T20:07:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sage-therapeutics-and-biogen-announce-topline-results-from-phase-2-kinetic-2-study-of-sage-324-biib124-for-the-treatment-of-essential-tremor 2024-07-24T20:07:46+00:00 weekly 0.7 https://trial.medpath.com/news/triastek-and-biontech-partner-to-develop-3d-printed-oral-rna-therapeutics-in-1-2-billion-deal 2024-07-24T10:27:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/triastek-and-biontech-partner-to-develop-3d-printed-oral-rna-therapeutics-in-1-2-billion-deal 2024-07-24T10:27:25+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-announces-positive-topline-results-from-phase-3-study-of-hemophilia-a-gene-therapy-candidate-giroctocogene-fitelparvovec 2024-07-24T03:07:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-announces-positive-topline-results-from-phase-3-study-of-hemophilia-a-gene-therapy-candidate-giroctocogene-fitelparvovec 2024-07-24T03:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/vivacelle-bio-initiates-phase-3-trial-for-lead-asset-vbi-s-to-treat-patients-with-hypovolemia-due-to-septic-shock 2024-07-24T03:07:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivacelle-bio-initiates-phase-3-trial-for-lead-asset-vbi-s-to-treat-patients-with-hypovolemia-due-to-septic-shock 2024-07-24T03:07:02+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-food-and-drug-administration-approves-biomarin-s-brineura-cerliponase-alfa-for-children-under-3-years-with-cln2-disease 2024-07-24T01:07:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/u-s-food-and-drug-administration-approves-biomarin-s-brineura-cerliponase-alfa-for-children-under-3-years-with-cln2-disease 2024-07-24T01:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/consynance-therapeutics-receives-fda-rare-pediatric-disease-designation-for-csti-500-in-prader-willi-syndrome 2024-07-24T01:07:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/consynance-therapeutics-receives-fda-rare-pediatric-disease-designation-for-csti-500-in-prader-willi-syndrome 2024-07-24T01:07:11+00:00 weekly 0.7 https://trial.medpath.com/news/glecirasib-a-promising-novel-kras-g12c-inhibitor-in-clinical 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glecirasib-a-promising-novel-kras-g12c-inhibitor-in-clinical 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/spectral-medical-provides-tigris-trial-update-biospace 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spectral-medical-provides-tigris-trial-update-biospace 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/nci-launches-cervical-cancer-last-mile-initiative-to-expand-screening-access 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nci-launches-cervical-cancer-last-mile-initiative-to-expand-screening-access 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bio-thera-solutions-announces-regulatory-filing-acceptance-for-bat2206-a-proposed-biosimilar-to-stelara-r-in-the-us-and-eu 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bio-thera-solutions-announces-regulatory-filing-acceptance-for-bat2206-a-proposed-biosimilar-to-stelara-r-in-the-us-and-eu 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/new-gene-therapy-approach-shows-promise-for-duchenne-muscular-dystrophy 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-gene-therapy-approach-shows-promise-for-duchenne-muscular-dystrophy 2024-07-24T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-femlyv-norethindrone-acetate-and-ethinyl-estradiol-orally-disintegrating-birth-control-pill 2024-07-23T23:07:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-femlyv-norethindrone-acetate-and-ethinyl-estradiol-orally-disintegrating-birth-control-pill 2024-07-23T23:07:51+00:00 weekly 0.7 https://trial.medpath.com/news/merz-aesthetics-announces-fda-approval-of-xeomin-incobotulinumtoxina-as-the-first-and-only-u-s-neurotoxin-for-the-simultaneous-treatment-of-upper-facial-lines 2024-07-23T22:07:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merz-aesthetics-announces-fda-approval-of-xeomin-incobotulinumtoxina-as-the-first-and-only-u-s-neurotoxin-for-the-simultaneous-treatment-of-upper-facial-lines 2024-07-23T22:07:08+00:00 weekly 0.7 https://trial.medpath.com/news/iopofosine-i-131-achieves-major-response-rate-in-relapsed-refractory-waldenstrom-macroglobulinemia 2024-07-23T16:22:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iopofosine-i-131-achieves-major-response-rate-in-relapsed-refractory-waldenstrom-macroglobulinemia 2024-07-23T16:22:41+00:00 weekly 0.7 https://trial.medpath.com/news/millions-more-brits-could-get-weight-loss-jabs-on-nhs-to-prevent-heart-attack-and-stroke-are-you-e 2024-07-23T16:20:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/millions-more-brits-could-get-weight-loss-jabs-on-nhs-to-prevent-heart-attack-and-stroke-are-you-e 2024-07-23T16:20:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-resubmission-of-bla-for-remestemcel-l-in-pediatric-steroid-refractory-acute-graft-vs-host-disease 2024-07-23T15:23:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-accepts-resubmission-of-bla-for-remestemcel-l-in-pediatric-steroid-refractory-acute-graft-vs-host-disease 2024-07-23T15:23:40+00:00 weekly 0.7